[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 1576
1. Tan Y, Li G, Zhao C, Wang J, Zhao H, Xue Y, Han M, Yang C: Expression of sorcin predicts poor outcome in acute myeloid leukemia. Leuk Res; 2003 Feb;27(2):125-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of sorcin predicts poor outcome in acute myeloid leukemia.
  • To determine the clinical role of sorcin, we have measured its expression in leukemic blast cells of 65 acute myeloid leukemia (AML) patients by reverse transcriptase polymerase chain reaction (RT-PCR).
  • Sorcin overexpression in AML patients was associated with poor clinical outcomes, the complete remission (CR) rate in sorcin- cases was significantly higher than that of sorcin+ cases (P<0.001).
  • Furthermore, sorcin expression in AML patients was positively correlated with mdr1 expression (r=0.841, P<0.001).
  • Our results indicated that sorcin might be one of the factors that contributes to drug resistance of AML patients.
  • [MeSH-major] Calcium-Binding Proteins / genetics. Gene Expression Regulation, Leukemic / genetics. Leukemia, Myeloid / diagnosis
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Aged. Child. Drug Resistance, Multiple / genetics. Drug Resistance, Neoplasm / genetics. Female. Gene Expression Profiling. Humans. K562 Cells. Male. Middle Aged. Neoplasm Proteins / genetics. Oligonucleotide Array Sequence Analysis. P-Glycoprotein / genetics. Prognosis. RNA, Messenger / analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12526918.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Calcium-Binding Proteins; 0 / Neoplasm Proteins; 0 / P-Glycoprotein; 0 / RNA, Messenger; 0 / SRI protein, human
  •  go-up   go-down


2. Su EY, Chen HS, Han YM: [Observation on treatment of post-remission acute myeloid leukemia patients by lingxiong piaoling powder and longchan cigu decoction]. Zhongguo Zhong Xi Yi Jie He Za Zhi; 2004 Feb;24(2):124-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Observation on treatment of post-remission acute myeloid leukemia patients by lingxiong piaoling powder and longchan cigu decoction].
  • OBJECTIVE: To explore the effect of the treatment for long-term disease-free survival (DFS) of post-remission patients with acute myeloid leukemia (AML).
  • METHODS: Twenty-nine AML patients with completely remission (CR) and 17 with partial remission (PR) were treated with Chinese medicine, Longchan Cigu Decoction 1 dose per day and Lingxiong Piaoling Powder 7 doses per month, and combined with DA or HA regimen of chemotherapy one course per year.
  • RESULTS: After treated with above mentioned treatment for 2 months, percentage of patients with normal peripheral blood count increased, including patients with WBC > or = 4.0 x 10(9)/L raised from 46% to 70%, with Hb > or = 120 g/L from 17% to 46% and with PLT > or = 100 x 10(9)/L from 63% to 85%; nucleated cell volume in bone marrow increased from 35.83 +/- 28.42% to 60.46 +/- 17.73% (P < 0.01); HLA-DR cell was also increased significantly from 10.55 +/- 4.95% to 14.84 +/- 4.94%, (P < 0.01); while the residual leukemia cells were not increased in one year, from 5.90 +/- 5.09% before and 5.82 +/- 2.42% after treatment (P > 0.05).
  • CONCLUSION: The integrative Chinese and western medicine treating program used in this study is beneficial for the long-term treatment of AML patients after complete remission.

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15015444.001).
  • [ISSN] 1003-5370
  • [Journal-full-title] Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine
  • [ISO-abbreviation] Zhongguo Zhong Xi Yi Jie He Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Drugs, Chinese Herbal; E7WED276I5 / 6-Mercaptopurine; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


3. Aswald JM, Wang XH, Aswald S, Lutynski A, Minden MD, Messner HA, Keating A: Flow cytometric assessment of autologous gammadelta T cells in patients with acute myeloid leukemia: potential effector cells for immunotherapy? Cytometry B Clin Cytom; 2006 Nov 15;70(6):379-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Flow cytometric assessment of autologous gammadelta T cells in patients with acute myeloid leukemia: potential effector cells for immunotherapy?
  • This population may be suitable for the adoptive immunotherapy of acute myeloid leukemia (AML).
  • Little is known however, about the frequency and function of circulating gammadelta T cells in AML.
  • The aim of the study was to enumerate peripheral blood gammadelta T cells in patients with AML and explore the feasibility of their use clinically.
  • METHODS: We compared the absolute circulating gammadelta T cell levels in 33 AML patients before and after treatment versus 20 healthy volunteers using flow cytometry.
  • RESULTS: AML patients with high blast counts prior to induction chemotherapy had marginally decreased gammadelta T cell levels compared with healthy controls: median 38/microL versus 83/microL; P = 0.051.
  • We also tested the functional properties of gammadelta T cells from patients with AML in CR.
  • CONCLUSION: Flow cytometric assessment of gammadelta T cells in patients with AML revealed quantitative shifts with respect to disease status.
  • Our data suggest that gammadelta T cells warrant further investigation as potential therapeutic agents.
  • [MeSH-major] Flow Cytometry / methods. Leukemia, Myeloid / immunology. Receptors, Antigen, T-Cell, gamma-delta / immunology. T-Lymphocytes / immunology
  • [MeSH-minor] Acute Disease. Adult. Aged. Aged, 80 and over. Cell Count. Feasibility Studies. Female. Humans. Immunotherapy. Male. Middle Aged. Neoplasm, Residual / immunology. Recurrence. Remission Induction. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 International Society for Analytical Cytology.
  • (PMID = 16977635.001).
  • [ISSN] 1552-4949
  • [Journal-full-title] Cytometry. Part B, Clinical cytometry
  • [ISO-abbreviation] Cytometry B Clin Cytom
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Antigen, T-Cell, gamma-delta
  •  go-up   go-down


Advertisement
4. Er TK, Tsai SM, Wu SH, Chiang W, Lin HC, Lin SF, Wu SH, Tsai LY, Liu TZ: Antioxidant status and superoxide anion radical generation in acute myeloid leukemia. Clin Biochem; 2007 Sep;40(13-14):1015-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antioxidant status and superoxide anion radical generation in acute myeloid leukemia.
  • OBJECTIVES: This study was undertaken to investigate if there is a disparity in the antioxidant status and the ability of superoxide anion (O(2)(-)) generation in the patients with acute myeloid leukemia (AML).
  • DESIGN AND METHODS: The peripheral blood samples from thirty AML patients and thirty-six healthy subjects were collected and leukocytes, erythrocytes and plasma were separated for use in various parameter measurements.
  • RESULTS: The generation of O(2)(-), as reflected by lucigenin-based CL (LBCL), by the leukocytes of patients with AML was found to be significantly elevated either in resting or stimuli-elicited condition as compared with that of healthy controls (p<0.05).
  • Coincidentally, these data were matched up with the suppressed SOD activities, notably in Cu/Zn SOD isoform found in AML patients (p<0.05).
  • Conversely, SOD and GPx activities in erythrocytes of patients with AML were shown to be significantly higher than their normal counterparts (p<0.05).
  • CONCLUSIONS: These data suggest that altered expression of antioxidant enzymes and higher capability of O(2)(-) generation by leukocytes seem to be a distinct feature of AML.
  • [MeSH-major] Antioxidants / metabolism. Leukemia, Myeloid / metabolism. Superoxides / metabolism
  • [MeSH-minor] Acute Disease. Adult. Case-Control Studies. Erythrocytes / drug effects. Erythrocytes / metabolism. Female. Glutathione Peroxidase / metabolism. Humans. Leukocytes / drug effects. Leukocytes / metabolism. Lipid Peroxidation / drug effects. Male. Middle Aged. Oxidation-Reduction / drug effects. Plasma / drug effects. Plasma / metabolism. Superoxide Dismutase / metabolism. Zymosan / pharmacology

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Antioxidants.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17628517.001).
  • [ISSN] 0009-9120
  • [Journal-full-title] Clinical biochemistry
  • [ISO-abbreviation] Clin. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antioxidants; 11062-77-4 / Superoxides; 9010-72-4 / Zymosan; EC 1.11.1.9 / Glutathione Peroxidase; EC 1.15.1.1 / Superoxide Dismutase
  •  go-up   go-down


5. Westling K, Julander I, Ljungman P, Heimdahl A, Thalme A, Nord CE: Reduced susceptibility to penicillin of viridans group streptococci in the oral cavity of patients with haematological disease. Clin Microbiol Infect; 2004 Oct;10(10):899-903
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The occurrence of oral penicillin-resistant viridans group streptococci (VGS) was studied in 50 patients with either newly diagnosed acute leukaemia or autologous peripheral stem cell transplants.
  • [MeSH-major] Leukemia, Myeloid, Acute / microbiology. Mouth Mucosa / microbiology. Penicillin Resistance. Precursor Cell Lymphoblastic Leukemia-Lymphoma / microbiology. Streptococcal Infections / microbiology. Viridans Streptococci / drug effects
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anti-Bacterial Agents / pharmacology. Female. Humans. Immunocompromised Host. Male. Microbial Sensitivity Tests. Middle Aged. Prospective Studies. Stem Cell Transplantation. Sweden. Trimethoprim, Sulfamethoxazole Drug Combination / pharmacology

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Streptococcal Infections.
  • Hazardous Substances Data Bank. TRIMETHOPRIM/SULFAMETHOXAZOLE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15373884.001).
  • [ISSN] 1198-743X
  • [Journal-full-title] Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
  • [ISO-abbreviation] Clin. Microbiol. Infect.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 8064-90-2 / Trimethoprim, Sulfamethoxazole Drug Combination
  •  go-up   go-down


6. Feldman E, Kalaycio M, Weiner G, Frankel S, Schulman P, Schwartzberg L, Jurcic J, Velez-Garcia E, Seiter K, Scheinberg D, Levitt D, Wedel N: Treatment of relapsed or refractory acute myeloid leukemia with humanized anti-CD33 monoclonal antibody HuM195. Leukemia; 2003 Feb;17(2):314-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of relapsed or refractory acute myeloid leukemia with humanized anti-CD33 monoclonal antibody HuM195.
  • Fifty adult patients with relapsed or refractory AML were randomized to receive HuM195 at a dose of 12 or 36 mg/m(2) by intravenous infusion over 4 h on days 1-4 and 15-18.
  • HuM195 as a single agent has minimal, but observable, anti-leukemic activity in patients with relapsed or refractory AML and activity is confined to patients with low burden disease.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antigens, CD / immunology. Antigens, Differentiation, Myelomonocytic / immunology. Leukemia, Promyelocytic, Acute / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Dose-Response Relationship, Drug. Female. Humans. Infusions, Intravenous. Male. Middle Aged. Salvage Therapy. Sialic Acid Binding Ig-like Lectin 3. Treatment Outcome

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12592328.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / CD33 protein, human; 0 / Sialic Acid Binding Ig-like Lectin 3
  •  go-up   go-down


7. Radich GP: Molecular characteristics therapy in AML. Clin Adv Hematol Oncol; 2009 Jun;7(6):11-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular characteristics therapy in AML.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Drugs, Investigational / therapeutic use. Leukemia, Myeloid / drug therapy. Neoplasm Proteins / genetics
  • [MeSH-minor] Acute Disease. Adult. Age Factors. Chromosome Aberrations. Clinical Trials as Topic. Combined Modality Therapy. Drug Delivery Systems. Drug Resistance, Neoplasm. Hematopoietic Stem Cell Transplantation. Humans. Multicenter Studies as Topic. Mutation. Risk Factors. Salvage Therapy. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19645131.001).
  • [ISSN] 1543-0790
  • [Journal-full-title] Clinical advances in hematology & oncology : H&O
  • [ISO-abbreviation] Clin Adv Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Drugs, Investigational; 0 / Neoplasm Proteins
  • [Number-of-references] 18
  •  go-up   go-down


8. Connolly R, Wolff AC: Pregnancy and fertility with breast cancer: what are the options? Oncology (Williston Park); 2009 May;23(6):478, 481
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant / adverse effects. Female. Heart Failure / chemically induced. Humans. Leukemia, Myeloid, Acute / chemically induced. Mastectomy, Segmental. Ovary / drug effects. Pregnancy. Premenopause


9. Weisdorf D: Rash and GI symptoms on day +36. Biol Blood Marrow Transplant; 2007 Nov;13(11):1405-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Graft vs Host Disease / drug therapy. Leukemia, Myeloid, Acute / therapy. Peripheral Blood Stem Cell Transplantation / adverse effects
  • [MeSH-minor] Adult. Cytomegalovirus Infections / therapy. Diarrhea / etiology. Diarrhea / therapy. Exanthema / drug therapy. Exanthema / etiology. Glucocorticoids / therapeutic use. Humans. Male. Prednisone / therapeutic use. Time Factors. Transplantation, Homologous

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17950925.001).
  • [ISSN] 1083-8791
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glucocorticoids; VB0R961HZT / Prednisone
  •  go-up   go-down


10. Devetten MP, Qazilbash MH, Beall CL, Bunner P, Weisenborn R, Lynch JP, Ericson SG: Thiotepa and fractionated TBI conditioning prior to allogeneic stem cell transplantation for advanced hematologic malignancies: a phase II single institution trial. Bone Marrow Transplant; 2004 Oct;34(7):577-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Relapse of hematologic malignancies after allogeneic stem cell transplantation remains a common problem, in particular for patients who have advanced disease at the time of transplantation.
  • Thiotepa has excellent antileukemic and immunosuppressive activity, and could therefore be a useful drug in the conditioning regimen for patients with advanced hematologic neoplasms.
  • [MeSH-major] Antineoplastic Agents, Alkylating / administration & dosage. Hematopoietic Stem Cell Transplantation. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Thiotepa / administration & dosage. Transplantation Conditioning. Whole-Body Irradiation
  • [MeSH-minor] Acute Disease. Adult. Combined Modality Therapy. Female. Graft vs Host Disease / mortality. Humans. Leukemia, Myeloid / drug therapy. Leukemia, Myeloid / mortality. Male. Middle Aged. Radiation Dosage. Recurrence. Retrospective Studies. Survival Analysis. Transplantation, Homologous

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • Hazardous Substances Data Bank. THIO-TEPA .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15286685.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 905Z5W3GKH / Thiotepa
  •  go-up   go-down


11. Hirschfeld S, Ho PT, Smith M, Pazdur R: Regulatory approvals of pediatric oncology drugs: previous experience and new initiatives. J Clin Oncol; 2003 Mar 15;21(6):1066-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Regulatory approvals of pediatric oncology drugs: previous experience and new initiatives.
  • PURPOSE: To review the Food and Drug Administration (FDA) experience with approvals of new drugs for pediatric oncology and to discuss new regulatory initiatives directed at pediatric oncology.
  • RESULTS: More than 100 drugs have been approved by the Division of Oncology Drug Products of the FDA for the treatment of malignancies.
  • Only 15 have pediatric use information in their labeling, which is less than 50% of the drugs commonly used in the treatment of pediatric malignancies.
  • CONCLUSION: Potential reasons for a lack of New Drug Application submissions for pediatric oncology include the small pediatric oncology market compared with the adult oncology market and perceived barriers to performing studies in children.
  • Regulatory initiatives to promote pediatric therapeutic development and product labeling are discussed.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Drug Approval
  • [MeSH-minor] Azacitidine / therapeutic use. Child. Child, Preschool. Humans. Leukemia, Myeloid, Acute / drug therapy. Methotrexate / therapeutic use. Neuroblastoma / drug therapy. Osteosarcoma / drug therapy. Pediatrics / standards. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Teniposide / therapeutic use. United States. United States Food and Drug Administration. Vindesine / therapeutic use

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. TENIPOSIDE .
  • Hazardous Substances Data Bank. AZACITIDINE .
  • Hazardous Substances Data Bank. VINDESINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12637472.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 957E6438QA / Teniposide; M801H13NRU / Azacitidine; RSA8KO39WH / Vindesine; YL5FZ2Y5U1 / Methotrexate
  • [Number-of-references] 26
  •  go-up   go-down


12. Lemoli RM, D'Addio A, Marotta G, Pezzullo L, Zuffa E, Montanari M, De Vivo A, Bonini A, Galieni P, Carella AM, Guidi S, Michieli M, Olivieri A, Bosi A: BU/melphalan and auto-SCT in AML patients in first CR: a 'Gruppo Italiano Trapianto di Midollo Osseo (GITMO)' retrospective study. Bone Marrow Transplant; 2010 Apr;45(4):640-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] BU/melphalan and auto-SCT in AML patients in first CR: a 'Gruppo Italiano Trapianto di Midollo Osseo (GITMO)' retrospective study.
  • AML patients (total 129; median age =50 years; range 16-72) in first CR received BU and melphalan (BU/Mel) as conditioning regimen before auto-SCT.
  • The relapse rate was 46% and the non-relapse mortality was 4.65%.
  • Our data suggest that BU/Mel, being associated with a low toxicity profile (mainly mucositis) and mortality, is an effective conditioning regimen even for high-risk AML patients in first CR undergoing auto-SCT.
  • [MeSH-major] Busulfan / therapeutic use. Hematopoietic Stem Cell Transplantation. Immunosuppressive Agents / therapeutic use. Leukemia, Myeloid, Acute / therapy. Melphalan / therapeutic use. Transplantation Conditioning / methods
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Bone Marrow Transplantation. Disease-Free Survival. Drug Therapy, Combination. Female. Humans. Italy. Kaplan-Meier Estimate. Male. Middle Aged. Peripheral Blood Stem Cell Transplantation. Retrospective Studies. Transplantation, Autologous. Young Adult

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. BUSULFAN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19802019.001).
  • [ISSN] 1476-5365
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; G1LN9045DK / Busulfan; Q41OR9510P / Melphalan
  •  go-up   go-down


13. Takeuchi J, Kyo T, Naito K, Sao H, Takahashi M, Miyawaki S, Kuriyama K, Ohtake S, Yagasaki F, Murakami H, Asou N, Ino T, Okamoto T, Usui N, Nishimura M, Shinagawa K, Fukushima T, Taguchi H, Morii T, Mizuta S, Akiyama H, Nakamura Y, Ohshima T, Ohno R: Induction therapy by frequent administration of doxorubicin with four other drugs, followed by intensive consolidation and maintenance therapy for adult acute lymphoblastic leukemia: the JALSG-ALL93 study. Leukemia; 2002 Jul;16(7):1259-66
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Induction therapy by frequent administration of doxorubicin with four other drugs, followed by intensive consolidation and maintenance therapy for adult acute lymphoblastic leukemia: the JALSG-ALL93 study.
  • In order to improve the disappointing prognosis of adult patients with acute lymphoblastic leukemia (ALL), we applied similar induction therapy as that used for acute myeloid leukemia (AML), ie frequent administration of doxorubicin (DOX).
  • From December 1993 to February 1997, 285 untreated adult patients with de novo ALL were entered.
  • [MeSH-major] Antibiotics, Antineoplastic / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Bone Marrow Transplantation. Doxorubicin / administration & dosage. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12094249.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; EC 3.5.1.1 / Asparaginase
  •  go-up   go-down


14. de Lima M, Anagnostopoulos A, Munsell M, Shahjahan M, Ueno N, Ippoliti C, Andersson BS, Gajewski J, Couriel D, Cortes J, Donato M, Neumann J, Champlin R, Giralt S: Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation. Blood; 2004 Aug 1;104(3):865-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation.
  • Intensity of the preparative regimen is an important component of allogeneic transplantations for myelodysplasia (MDS) or acute myelogenous leukemia (AML).
  • We performed a retrospective analysis of 94 patients with MDS (n = 26) and AML (n = 68) treated with FM (n = 62) and FAI (n = 32).
  • [MeSH-major] Immunosuppressive Agents / therapeutic use. Leukemia, Myeloid, Acute / therapy. Myelodysplastic Syndromes / therapy. Stem Cell Transplantation / methods. Transplantation Conditioning / methods
  • [MeSH-minor] Adult. Aged. Drug Therapy, Combination. Female. Humans. Male. Middle Aged. Patient Selection. Retrospective Studies. Survival Analysis. Transplantation, Homologous


15. Small D: Targeting FLT3 for the treatment of leukemia. Semin Hematol; 2008 Jul;45(3 Suppl 2):S17-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Targeting FLT3 for the treatment of leukemia.
  • It is frequently overexpressed in acute leukemias and is frequently mutated in acute myeloid leukemia (AML).
  • FLT3 internal tandem duplication (ITD) mutations in AML portend poor prognosis in both adult and pediatric patients.
  • Many of these are still in preclinical development, but several have entered clinical phase I and II trials as monotherapy in patients with relapsed AML.
  • Several combination trials are ongoing or planned in both relapsed and newly diagnosed FLT3-mutant AML patients.
  • Anti-FLT3 antibodies may also prove to be an excellent way of targeting FLT3 in AML and acute lymphocytic leukemia (ALL) by inhibiting signaling and through antibody-dependent cell-mediated cytotoxicity.

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2003 Nov 15;9(15):5465-76 [14654525.001]
  • [Cites] Eur J Cancer. 2004 Mar;40(5):707-21, discussion 722-4 [15010072.001]
  • [Cites] Blood. 2004 May 15;103(10):3669-76 [14726387.001]
  • [Cites] Blood. 2004 Aug 15;104(4):1145-50 [15126317.001]
  • [Cites] Blood. 2004 Sep 15;104(6):1841-9 [15166029.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Jan 18;91(2):459-63 [7507245.001]
  • [Cites] Blood. 1996 Feb 1;87(3):1089-96 [8562934.001]
  • [Cites] Leukemia. 1996 Dec;10(12):1911-8 [8946930.001]
  • [Cites] Blood. 2005 Jan 1;105(1):54-60 [15345597.001]
  • [Cites] Blood. 2005 Jan 15;105(2):812-20 [15374878.001]
  • [Cites] Blood. 2005 Feb 1;105(3):986-93 [15459012.001]
  • [Cites] Cancer Res. 2005 Feb 15;65(4):1514-22 [15735040.001]
  • [Cites] Blood. 2005 Nov 15;106(10):3658-65 [16076872.001]
  • [Cites] Cancer Res. 2006 May 1;66(9):4843-51 [16651440.001]
  • [Cites] Eur J Haematol. 2006 Jul;77(1):35-45 [16573742.001]
  • [Cites] Leukemia. 2006 Aug;20(8):1368-76 [16761017.001]
  • [Cites] Blood. 2006 Nov 15;108(10):3262-70 [16857985.001]
  • [Cites] Blood. 2006 Dec 1;108(12):3674-81 [16902153.001]
  • [Cites] Blood. 2006 Dec 1;108(12):3654-61 [16912228.001]
  • [Cites] Blood. 2007 Mar 1;109(5):2264-5; author reply 2265 [17312001.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Leukemia. 2000 Apr;14(4):675-83 [10764154.001]
  • [Cites] Blood. 2001 Jan 1;97(1):89-94 [11133746.001]
  • [Cites] Blood. 2001 Apr 15;97(8):2434-9 [11290608.001]
  • [Cites] Blood. 2001 Aug 1;98(3):885-7 [11468194.001]
  • [Cites] Blood. 2002 Jun 1;99(11):3885-91 [12010785.001]
  • [Cites] Blood. 2002 Jun 15;99(12):4326-35 [12036858.001]
  • [Cites] Curr Opin Hematol. 2002 Jul;9(4):274-81 [12042700.001]
  • [Cites] Leukemia. 2003 Sep;17(9):1738-52 [12970773.001]
  • (PMID = 18760705.001).
  • [ISSN] 0037-1963
  • [Journal-full-title] Seminars in hematology
  • [ISO-abbreviation] Semin. Hematol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA090668; United States / NCI NIH HHS / CA / P01 CA070970; United States / NCI NIH HHS / CA / R01 CA090668-01A1; United States / NCI NIH HHS / CA / CA090668-01A1; United States / NCI NIH HHS / CA / P01 CA070970-10A16432; United States / NCI NIH HHS / CA / CA070970-10A16432
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies; 0 / Protein Kinase Inhibitors; EC 2.7.10.1 / FLT3 protein, human; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3
  • [Number-of-references] 34
  • [Other-IDs] NLM/ NIHMS69701; NLM/ PMC2597087
  •  go-up   go-down


16. Rombouts WJ, Löwenberg B, van Putten WL, Ploemacher RE: Improved prognostic significance of cytokine-induced proliferation in vitro in patients with de novo acute myeloid leukemia of intermediate risk: impact of internal tandem duplications in the Flt3 gene. Leukemia; 2001 Jul;15(7):1046-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improved prognostic significance of cytokine-induced proliferation in vitro in patients with de novo acute myeloid leukemia of intermediate risk: impact of internal tandem duplications in the Flt3 gene.
  • The heterogeneity of acute myeloid leukemia is reflected in many clinical, biological and genetic features that are used to predict the response to therapy.
  • In an attempt to further characterize the heterogeneity of prognosis among the cytogenetic intermediate risk group of AML, we investigated the overall survival, failure-free survival, initial therapy response and relapse rates of 103 patients with de novo AML in relation to autonomous proliferation and the proliferative response to a panel of 10 cytokines in a short-term thymidine incorporation assay.
  • [MeSH-major] Cytokines / pharmacology. Leukemia, Myeloid, Acute / pathology. Proto-Oncogene Proteins / genetics. Receptor Protein-Tyrosine Kinases / genetics. Tandem Repeat Sequences
  • [MeSH-minor] Adolescent. Adult. Aged. Cell Division / drug effects. Female. Humans. Male. Middle Aged. Prognosis. fms-Like Tyrosine Kinase 3

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11455972.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cytokines; 0 / Proto-Oncogene Proteins; EC 2.7.10.1 / FLT3 protein, human; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3
  •  go-up   go-down


17. Arruda VR, Lima CS, Grignoli CR, de Melo MB, Lorand-Metze I, Alberto FL, Saad ST, Costa FF: Increased risk for acute myeloid leukaemia in individuals with glutathione S-transferase mu 1 (GSTM1) and theta 1 (GSTT1) gene defects. Eur J Haematol; 2001 Jun;66(6):383-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased risk for acute myeloid leukaemia in individuals with glutathione S-transferase mu 1 (GSTM1) and theta 1 (GSTT1) gene defects.
  • OBJECTIVES: Glutathione S-transferases (GST) modulate the effects of exposure to various cytotoxic and genotoxic agents, including those associated with increased risks of the myelodysplastic syndrome (MDS), acute myeloid leukaemia (AML) and aplastic anemia (AA).
  • In this study, we tested whether null genotypes for the GSTM1 and GSTT1 genes altered the risks for MDS, AML and AA.
  • METHODS: Genomic DNA from 49 MDS, 38 AML and 37 AA patients and 276 controls was analysed using the polymerase chain reaction (PCR).
  • RESULTS: The frequencies of GSTM1 (73.6%) and GSTT1 (34.2%) null genotypes were significantly higher in AML patients than in the controls (36.9 and 18.1%, respectively).
  • A higher frequency of the combined null genotype for both genes was also observed in patients with AML (26.3% compared with 5.0% in the controls).
  • CONCLUSION: Our observation of a 4.7-fold (95% CI: 2.1-11.0) and 2.3-fold (95% CI: 1.0-5.2) increased risk associated with the GSTM1 and GSTT1 null genotypes, respectively, and a 6.6-fold (95% CI: 2.4-7.9) increased risk associated with the combined null genotype presents preliminary evidence that the inherited absence of this carcinogen detoxification pathway may be an important determinant of AML.
  • [MeSH-major] Glutathione Transferase / genetics. Leukemia, Myeloid / genetics
  • [MeSH-minor] Acute Disease. Adult. Alleles. Anemia, Aplastic / diagnosis. Anemia, Aplastic / etiology. Anemia, Aplastic / genetics. Case-Control Studies. Female. Gene Deletion. Gene Frequency. Genetic Predisposition to Disease. Hazardous Substances / adverse effects. Humans. Male. Middle Aged. Myelodysplastic Syndromes / diagnosis. Myelodysplastic Syndromes / etiology. Myelodysplastic Syndromes / genetics. Risk Factors

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11488937.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Hazardous Substances; EC 2.5.1.- / glutathione S-transferase T1; EC 2.5.1.18 / Glutathione Transferase; EC 2.5.1.18 / glutathione S-transferase M1
  •  go-up   go-down


18. Preisler HD, Venugopal P, Gregory SA, Adler S, Gezer S, Hsu WT, Manson S, Larson A, Jajeh A, Slvinick D, Galvez A: High remission rate in acute myeloblastic leukemia with only two days of chemotherapy. Leuk Lymphoma; 2001 Apr;41(3-4):333-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High remission rate in acute myeloblastic leukemia with only two days of chemotherapy.
  • Twenty five patients with AML who had neither a history of toxic exposure or myelodysplasia were treated with a remission induction regimen consisting of two pulses of chemotherapy separated by 96 hrs.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Leukemia, Myeloid, Acute / drug therapy
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Cohort Studies. Cytarabine / administration & dosage. Cytarabine / standards. Cytogenetic Analysis. Drug Administration Schedule. Humans. Middle Aged. Mitoxantrone / administration & dosage. Mitoxantrone / standards. Remission Induction. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11378545.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 04079A1RDZ / Cytarabine; BZ114NVM5P / Mitoxantrone
  •  go-up   go-down


19. Rogers PC, Meacham LR, Oeffinger KC, Henry DW, Lange BJ: Obesity in pediatric oncology. Pediatr Blood Cancer; 2005 Dec;45(7):881-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A recent Children's Oncology Group symposium considered epidemiology of obesity, pharmacology of chemotherapy and outcomes in obese adults with cancer, excess mortality in obese pediatric patients with acute myeloid leukemia (AML), and complications in obese survivors.
  • Pharmacologic investigations are few and limited: half-life, volume of distribution, and clearance in obese patients vary between drugs.
  • Obese adults with solid tumors generally experience less toxicity, suggesting underdosing.
  • For patients undergoing bone marrow transplantation, obese adults generally experience greater toxicity.
  • In pediatric acute myeloblastic leukemia, obese patients have greater treatment-related mortality (TRM), similar toxicity and relapse rates, and inferior survival compared with patients who are not obese.
  • An excess of female survivors of childhood leukemia who received cranial irradiation are obese.
  • [MeSH-major] Leukemia, Myeloid, Acute. Obesity. Precursor Cell Lymphoblastic Leukemia-Lymphoma
  • [MeSH-minor] Adolescent. Adult. Age Factors. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Body Mass Index. Bone Marrow Transplantation. Child. Child, Preschool. Female. Humans. Life Style. Male. Recurrence. Treatment Outcome


20. Metan G, Durusu M, Uzun O: False positivity for Aspergillus antigenemia with amoxicillin-clavulonic acid. J Clin Microbiol; 2005 May;43(5):2548; author reply 2548-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Amoxicillin / therapeutic use. Antigens, Fungal / blood. Aspergillosis / drug therapy. Clavulanic Acid / therapeutic use
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cohort Studies. Drug Therapy, Combination. False Positive Reactions. Female. Humans. Leukemia, Myeloid, Acute / drug therapy

  • MedlinePlus Health Information. consumer health - Aspergillosis.
  • Hazardous Substances Data Bank. AMOXICILLIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2001 Mar 15;97(6):1604-10 [11238098.001]
  • [Cites] Clin Infect Dis. 2002 Jan 1;34(1):7-14 [11731939.001]
  • [Cites] Clin Infect Dis. 2004 Mar 15;38(6):913-6 [14999640.001]
  • [Cites] J Clin Microbiol. 2004 Jun;42(6):2733-41 [15184460.001]
  • [Cites] Clin Infect Dis. 2004 Jul 15;39(2):289-90 [15307045.001]
  • [Cites] J Clin Microbiol. 2004 Oct;42(10):4744-8 [15472335.001]
  • [Cites] J Clin Microbiol. 1997 Jan;35(1):257-60 [8968919.001]
  • [Cites] J Clin Microbiol. 2004 Nov;42(11):5362-3 [15528743.001]
  • (PMID = 15876572.001).
  • [ISSN] 0095-1137
  • [Journal-full-title] Journal of clinical microbiology
  • [ISO-abbreviation] J. Clin. Microbiol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Fungal; 23521W1S24 / Clavulanic Acid; 804826J2HU / Amoxicillin
  • [Other-IDs] NLM/ PMC1153800
  •  go-up   go-down


21. Disel U, Paydas S, Yavuz S, Tuncer I, Alpay R: Bilateral ear Sweet's syndrome in a case with relapse acute myeloblastic leukemia. Leuk Res; 2006 Mar;30(3):364
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bilateral ear Sweet's syndrome in a case with relapse acute myeloblastic leukemia.
  • [MeSH-major] Ear, External / pathology. Leukemia, Myeloid, Acute / drug therapy. Sweet Syndrome / drug therapy
  • [MeSH-minor] Adult. Anti-Inflammatory Agents / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Cytarabine / administration & dosage. Female. Filgrastim. Granulocyte Colony-Stimulating Factor / administration & dosage. Humans. Idarubicin / administration & dosage. Methylprednisolone / administration & dosage. Neutropenia / drug therapy. Neutropenia / etiology. Neutropenia / pathology. Recombinant Proteins. Recurrence. Vidarabine / administration & dosage. Vidarabine / analogs & derivatives

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. Filgrastim .
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • Hazardous Substances Data Bank. METHYLPREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leuk Res. 2006 Nov;30(11):1466-8 [16540169.001]
  • (PMID = 16157374.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Recombinant Proteins; 04079A1RDZ / Cytarabine; 143011-72-7 / Granulocyte Colony-Stimulating Factor; FA2DM6879K / Vidarabine; PVI5M0M1GW / Filgrastim; X4W7ZR7023 / Methylprednisolone; ZRP63D75JW / Idarubicin; Ida-FLAG protocol
  •  go-up   go-down


22. Korycka A, Smolewski P, Robak T: The influence of farnesyl protein transferase inhibitor R115777 (Zarnestra) alone and in combination with purine nucleoside analogs on acute myeloid leukemia progenitors in vitro. Eur J Haematol; 2004 Dec;73(6):418-26
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The influence of farnesyl protein transferase inhibitor R115777 (Zarnestra) alone and in combination with purine nucleoside analogs on acute myeloid leukemia progenitors in vitro.
  • Recently it has also been considered as a drug of promise in hematologic malignancies such as acute myeloid leukemia (AML), especially in older patients, in chronic myelogenous leukemia (CML) as well as myelodysplastic syndromes (MDS).
  • The aim of our study was to evaluate the influence of R115777 used alone or with purine nucleoside analogs (PNA): cladribine (2-CdA) and fludarabine (F-ara-A) on leukemic progenitors [colony-forming unit-leukemia (CFU)-L] from AML patients.
  • We showed that R115777 used alone or together with PNA at all combinations significantly inhibited the colony growth of AML CFU-L, when compared with normal CFU-GM (P < 0.01).
  • In addition, the drugs used in combinations of two higher concentrations in significantly higher degree inhibited CFU-L colony growth, when compared either with R115777 or with any of PNA used alone (P < 0.04).
  • IC(50) for R115777 were 67.1 and 121.9 nm for AML CFU-L and normal CFU-GM, respectively.
  • Furthermore, in the case of AML the combination index was 0.89 and 1.16, respectively, for the combination of R115777 with 2-CdA and R115777 with F-ara-A.
  • An additive effect on AML CFU-L cells and subadditive effect on normal CFU-GM were seen.
  • To assess a proapoptotic effect, the drugs were added to the liquid cultures at the same concentrations as for clonogenic assays.
  • A significant increase in the rate of apoptosis induced by combinations of drugs in comparison with single agents was observed.
  • In conclusion, the combination of R115777 with both PNA could be more effective than the drugs used alone.
  • However, further experimental studies on the usefulness of these combinations in the treatment of myeloid leukemia patients are warranted.
  • [MeSH-major] Antimetabolites, Antineoplastic / pharmacology. Cladribine / pharmacology. Enzyme Inhibitors / pharmacology. Leukemia, Myeloid / pathology. Quinolones / pharmacology. Vidarabine / analogs & derivatives. Vidarabine / pharmacology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Drug Screening Assays, Antitumor. Drug Synergism. Female. Humans. In Vitro Techniques. Male. Middle Aged. Tumor Cells, Cultured / drug effects. Tumor Stem Cell Assay

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. CLADRIBINE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15522064.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Enzyme Inhibitors; 0 / Quinolones; 192185-72-1 / tipifarnib; 47M74X9YT5 / Cladribine; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  •  go-up   go-down


23. Janssens PM, Beerendonk CC, Blokzijl E, Braat DD, Westphal JR, Kremer JA: [Cryopreservation of semen of adolescents and young adult men with cancer]. Ned Tijdschr Geneeskd; 2004 Oct 2;148(40):1981-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cryopreservation of semen of adolescents and young adult men with cancer].
  • A 28-year-old man with chronic myeloid leukaemia that resulted in azoospermia, later fathered a child with his semen that had been stored prior to chemotherapy.
  • In an 18-year-old adolescent with non-Hodgkin lymphoma the possibility to store cryopreserved semen was only raised after chemotherapy had been started and had caused azoospermia.
  • A 14-year-old boy with acute lymphatic leukaemia had his semen stored despite initial hesitations due to his young age.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Cryopreservation. Oligospermia / chemically induced. Semen Preservation / methods
  • [MeSH-minor] Adolescent. Adult. Humans. Leukemia, Myeloid / drug therapy. Lymphoma, Non-Hodgkin / drug therapy. Male. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Semen / drug effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15524135.001).
  • [ISSN] 0028-2162
  • [Journal-full-title] Nederlands tijdschrift voor geneeskunde
  • [ISO-abbreviation] Ned Tijdschr Geneeskd
  • [Language] dut
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


24. Schimmer AD, Estey EH, Borthakur G, Carter BZ, Schiller GJ, Tallman MS, Altman JK, Karp JE, Kassis J, Hedley DW, Brandwein J, Xu W, Mak DH, LaCasse E, Jacob C, Morris SJ, Jolivet J, Andreeff M: Phase I/II trial of AEG35156 X-linked inhibitor of apoptosis protein antisense oligonucleotide combined with idarubicin and cytarabine in patients with relapsed or primary refractory acute myeloid leukemia. J Clin Oncol; 2009 Oct 01;27(28):4741-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I/II trial of AEG35156 X-linked inhibitor of apoptosis protein antisense oligonucleotide combined with idarubicin and cytarabine in patients with relapsed or primary refractory acute myeloid leukemia.
  • PURPOSE: X-linked inhibitor of apoptosis protein (XIAP) is an inhibitor of caspases 3 and 9 which are overexpressed in acute myeloid leukemia (AML) and may contribute to chemoresistance.
  • PATIENTS AND METHODS: Twenty-four patients with rapidly relapsed or refractory AML were treated with escalating doses of AEG35156 (12 to 250 mg/m(2)) as an intravenous solution over 2 hours and 32 patients were treated with the highest planned dose of 350 mg/m(2) in combination with idarubicin and high-dose cytarabine reinduction chemotherapy.
  • CONCLUSION: At the highest dose tested, AEG35156 knocks down its target and appears very effective when combined with chemotherapy in patients with AML refractory to a single induction regimen.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Myeloid / drug therapy
  • [MeSH-minor] Acute Disease. Adult. Aged. Cytarabine / administration & dosage. Cytarabine / adverse effects. Dose-Response Relationship, Drug. Drug Resistance, Neoplasm. Female. Gene Expression Regulation, Neoplastic / drug effects. Humans. Idarubicin / administration & dosage. Idarubicin / adverse effects. Male. Middle Aged. Oligonucleotides / administration & dosage. Peripheral Nervous System Diseases / chemically induced. RNA, Messenger / genetics. RNA, Messenger / metabolism. Recurrence. Reverse Transcriptase Polymerase Chain Reaction. Treatment Outcome. X-Linked Inhibitor of Apoptosis Protein / genetics

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4496-504 [14673036.001]
  • [Cites] Nature. 1999 Oct 21;401(6755):818-22 [10548111.001]
  • [Cites] Blood. 2006 Jul 15;108(2):419-25 [16609072.001]
  • [Cites] Leukemia. 2003 Nov;17(11):2081-9 [12970762.001]
  • [Cites] J Clin Oncol. 2009 Apr 1;27(10):1660-6 [19237630.001]
  • [Cites] Am J Hematol. 2008 Jan;83(1):54-8 [17696207.001]
  • [Cites] Blood. 2002 Dec 1;100(12):3869-76 [12393614.001]
  • [Cites] Blood. 2005 May 15;105(10):4043-50 [15687241.001]
  • [Cites] Mol Cell. 2003 Feb;11(2):519-27 [12620238.001]
  • [Cites] Cell. 2001 Mar 9;104(5):791-800 [11257232.001]
  • [Cites] Cancer Cell. 2004 Jan;5(1):25-35 [14749124.001]
  • [Cites] Clin Cancer Res. 2003 Jul;9(7):2826-36 [12855663.001]
  • [Cites] Br J Cancer. 2005 Feb 14;92(3):532-8 [15685240.001]
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4642-9 [14673054.001]
  • [Cites] Nature. 1997 Jul 17;388(6639):300-4 [9230442.001]
  • [Cites] Ann N Y Acad Sci. 2005 Nov;1058:215-34 [16394139.001]
  • [Cites] Int J Cancer. 2008 Mar 15;122(6):1430-4 [18027851.001]
  • (PMID = 19652057.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / AEG 35156; 0 / Oligonucleotides; 0 / RNA, Messenger; 0 / X-Linked Inhibitor of Apoptosis Protein; 04079A1RDZ / Cytarabine; ZRP63D75JW / Idarubicin
  •  go-up   go-down


25. Yuki F, Kawaguchi T, Hazemoto K, Asou N: [Preventive effects of oren-gedoku-to on mucositis caused by anticancer agents in patients with acute leukemia]. Gan To Kagaku Ryoho; 2003 Sep;30(9):1303-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Preventive effects of oren-gedoku-to on mucositis caused by anticancer agents in patients with acute leukemia].
  • Most anticancer agents frequently cause mucositis, such as stomatitis and gastrointestinal mucosal injury, which is closely associated with decrease in quality of life, infections and discontinuation of chemotherapy in patients with malignancy.
  • We retrospectively evaluated the preventive effect of oral administration of oren-gedoku-to on stomatitis and diarrhea induced by cytotoxic drugs in 40 patients with acute leukemia.
  • Drug-induced diarrhea was observed in 9.3% of the oren-gedoku-to group compared with 31.7% of the control group.
  • These observations indicate a significant preventive effect of oren-gedoku-to on mucositis caused by anticancer agents.
  • [MeSH-major] Anti-Inflammatory Agents, Non-Steroidal / therapeutic use. Antineoplastic Agents / adverse effects. Drugs, Chinese Herbal / therapeutic use. Leukemia, Myeloid / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Stomatitis / prevention & control
  • [MeSH-minor] Acute Disease. Adult. Aged. Diarrhea / prevention & control. Female. Humans. Male. Middle Aged. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14518410.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Antineoplastic Agents; 0 / Drugs, Chinese Herbal; 0 / oren gedoku to
  •  go-up   go-down


26. He K, Lago MW, Iyer RA, Shyu WC, Humphreys WG, Christopher LJ: Lacteal secretion, fetal and maternal tissue distribution of dasatinib in rats. Drug Metab Dispos; 2008 Dec;36(12):2564-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Dasatinib [N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide; BMS-354825] is a potent and broad-spectrum kinase inhibitor used for the treatment of chronic myeloid leukemia and Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia.
  • In summary, dasatinib was extensively distributed in maternal tissues and secreted into milk, but its penetration into the adult brain was limited.
  • Transporters may be involved in mediating dasatinib distribution in the adult rat, whereas in the fetus, tissue and blood exposures were similar, suggesting that distribution in the fetus is predominantly mediated by diffusion.
  • [MeSH-minor] Animals. Area Under Curve. Autoradiography. Dasatinib. Female. Molecular Structure. Pregnancy. Protein Kinase Inhibitors / metabolism. Protein Kinase Inhibitors / pharmacokinetics. Rats. Rats, Sprague-Dawley. Tissue Distribution

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18787054.001).
  • [ISSN] 1521-009X
  • [Journal-full-title] Drug metabolism and disposition: the biological fate of chemicals
  • [ISO-abbreviation] Drug Metab. Dispos.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protein Kinase Inhibitors; 0 / Pyrimidines; 0 / Thiazoles; RBZ1571X5H / Dasatinib
  •  go-up   go-down


27. Flaig TW, Tangen CM, Hussain MH, Stadler WM, Raghavan D, Crawford ED, Glodé LM, Southwest Oncology Group: Randomization reveals unexpected acute leukemias in Southwest Oncology Group prostate cancer trial. J Clin Oncol; 2008 Mar 20;26(9):1532-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomization reveals unexpected acute leukemias in Southwest Oncology Group prostate cancer trial.
  • RESULTS: In January 2007, SWOG 9921 was closed to further accrual after three cases of acute myelogenous leukemia (AML) were reported of a total of 487 patients in the mitoxantrone treatment arm.
  • Time from the start of mitoxantrone to the detection of AML was 13, 48, and 72 months, respectively.
  • Before SWOG 9921, there were no cases of mitoxantrone-induced AML reported in patients treated for prostate cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Leukemia, Myeloid, Acute / chemically induced. Leukemia, Myeloid, Acute / diagnosis. Mitoxantrone / administration & dosage. Mitoxantrone / adverse effects. Prostatectomy. Prostatic Neoplasms / drug therapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adult. Aged. Aged, 80 and over. Anilides / administration & dosage. Chemotherapy, Adjuvant / adverse effects. Fatal Outcome. Goserelin / administration & dosage. Humans. Male. Middle Aged. Nitriles / administration & dosage. Prednisone / administration & dosage. Risk Assessment. Risk Factors. Southwestern United States / epidemiology. Survival Analysis. Tosyl Compounds / administration & dosage

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. GOSERELIN .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • Hazardous Substances Data Bank. BICALUTAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18349405.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA04919; United States / NCI NIH HHS / CA / CA27057; United States / NCI NIH HHS / CA / CA32102; United States / NCI NIH HHS / CA / CA38926; United States / NCI NIH HHS / CA / CA41287; United States / NCI NIH HHS / CA / CA42777
  • [Publication-type] Case Reports; Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anilides; 0 / Nitriles; 0 / Tosyl Compounds; 0F65R8P09N / Goserelin; A0Z3NAU9DP / bicalutamide; BZ114NVM5P / Mitoxantrone; VB0R961HZT / Prednisone
  •  go-up   go-down


28. Bhatia S, Krailo MD, Chen Z, Burden L, Askin FB, Dickman PS, Grier HE, Link MP, Meyers PA, Perlman EJ, Rausen AR, Robison LL, Vietti TJ, Miser JS: Therapy-related myelodysplasia and acute myeloid leukemia after Ewing sarcoma and primitive neuroectodermal tumor of bone: A report from the Children's Oncology Group. Blood; 2007 Jan 1;109(1):46-51
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapy-related myelodysplasia and acute myeloid leukemia after Ewing sarcoma and primitive neuroectodermal tumor of bone: A report from the Children's Oncology Group.
  • This study describes the magnitude of risk of therapy-related myelodysplasia and acute myeloid leukemia (t-MDS/AML) in 578 individuals diagnosed with Ewing sarcoma and enrolled on Children's Oncology Group therapeutic protocol, INT-0091.
  • Between 1988 and 1992, patients with or without metastatic disease were randomized to receive doxorubicin, vincristine, cyclophosphamide, and dactinomycin (regimen A) or these 4 drugs alternating with etoposide and ifosfamide (regimen B).
  • Eleven patients developed t-MDS/AML, resulting in a cumulative incidence of 2% at 5 years.
  • While patients treated on regimens A and B were at a low risk for development of t-MDS/AML (cumulative incidence: 0.4% and 0.9% at 5 years, respectively), patients treated on regimen C were at a 16-fold increased risk of developing t-MDS/AML (cumulative incidence: 11% at 5 years), when compared with those treated on regimen A.
  • Increasing exposure to ifosfamide from 90 to 140 g/m2, cyclophosphamide from 9.6 to 17.6 g/m2, and doxorubicin from 375 to 450 mg/m2 increased the risk of t-MDS/AML significantly.


29. Foss B, Ulvestad E, Bruserud O: Platelet-derived growth factor (PDGF) in human acute myelogenous leukemia: PDGF receptor expression, endogenous PDGF release and responsiveness to exogenous PDGF isoforms by in vitro cultured acute myelogenous leukemia blasts. Eur J Haematol; 2001 Jun;66(6):365-76
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Platelet-derived growth factor (PDGF) in human acute myelogenous leukemia: PDGF receptor expression, endogenous PDGF release and responsiveness to exogenous PDGF isoforms by in vitro cultured acute myelogenous leukemia blasts.
  • We investigated effects of Platelet-derived growth factor (PDGF) and Platelet factor 4 (PF-4) on the functional characteristics of native, human acute myelogenous leukemia (AML) blasts.
  • AML blast expression of the PDGF-receptor alpha-chain was detected for a subset of patients (45%), whereas PDGF-receptor beta-chain expression was detected for most patients (90%).
  • Constitutive AML blast release of the PDGF-AB isoform (the major form also derived from normal platelets) was detected for 43% of patients, whereas PDGF-BB release was not detected for any patient.
  • The PDGF isoforms AA, AB and BB had dose-dependent and divergent effects on spontaneous and cytokine-dependent AML blast proliferation, whereas for constitutive cytokine secretion (IL-1beta, IL-6, TNF-alpha) inhibitory effects were rare and all three isoforms usually had no effect or enhanced the constitutive secretion.
  • The PDGF effects were caused by a direct effect on the AML blasts and were not dependent on the presence of serum.
  • The PDGF effects could also be detected after in vitro culture of AML cells in the presence of IL-4+granulocyte-macrophage colony stimulating factor.
  • PF-4 had divergent effects on proliferation and cytokine secretion by native AML blasts.
  • Our results suggest that exogenous (e.g. platelet-secreted) PDGF and PF-4 can function as regulators of leukemic hematopoiesis and possibly also modulate the function of residual AML cells in peripheral blood stem cell grafts.
  • [MeSH-major] Leukemia, Myeloid, Acute / metabolism. Platelet-Derived Growth Factor / pharmacology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Division / drug effects. Cytokines / drug effects. Cytokines / secretion. Female. Humans. Male. Middle Aged. Platelet Factor 4 / pharmacology. Protein Isoforms / metabolism. Protein Isoforms / pharmacology. Protein Isoforms / secretion. Receptors, Platelet-Derived Growth Factor / metabolism. Tumor Cells, Cultured / drug effects

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [RepublishedIn] Eur J Haematol. 2001 Oct;67(4):267-78 [11860452.001]
  • (PMID = 11488935.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Cytokines; 0 / Platelet-Derived Growth Factor; 0 / Protein Isoforms; 37270-94-3 / Platelet Factor 4; EC 2.7.10.1 / Receptors, Platelet-Derived Growth Factor
  •  go-up   go-down


30. Christiansen DH, Andersen MK, Pedersen-Bjergaard J: Mutations of AML1 are common in therapy-related myelodysplasia following therapy with alkylating agents and are significantly associated with deletion or loss of chromosome arm 7q and with subsequent leukemic transformation. Blood; 2004 Sep 1;104(5):1474-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mutations of AML1 are common in therapy-related myelodysplasia following therapy with alkylating agents and are significantly associated with deletion or loss of chromosome arm 7q and with subsequent leukemic transformation.
  • The AML1 transcription factor is essential for normal hematopoiesis and is the target of several chromosomal translocations in acute leukemia.
  • Acquired somatic AML1 mutations were recently demonstrated sporadically in de novo myelodysplasia (MDS) and acute myeloid leukemia (AML) including a few cases of therapy-related disease (t-MDS/t-AML).
  • We examined 140 patients with t-MDS or t-AML for AML1 mutations by direct sequencing.
  • Nineteen patients with AML1 mutations had previously received alkylating agents whereas 2 patients had received radiotherapy only.
  • AML1 mutations were highly significantly associated with presentation of the disease as t-MDS (P =.003), with deletion or loss of chromosome arm 7q (P =.001) and with subsequent transformation to overt t-AML (P =.0001).
  • [MeSH-major] Chromosome Deletion. Chromosomes, Human, Pair 7. DNA-Binding Proteins / genetics. Leukemia, Myeloid / genetics. Proto-Oncogene Proteins / genetics. Transcription Factors / genetics
  • [MeSH-minor] Acute Disease. Adult. Aged. Antineoplastic Agents, Alkylating / adverse effects. Cell Transformation, Neoplastic. Codon, Nonsense. Core Binding Factor Alpha 2 Subunit. Female. Frameshift Mutation. Humans. In Situ Hybridization, Fluorescence. Loss of Heterozygosity. Male. Middle Aged. Mutation, Missense. Polymorphism, Single Nucleotide

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15142876.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Codon, Nonsense; 0 / Core Binding Factor Alpha 2 Subunit; 0 / DNA-Binding Proteins; 0 / Proto-Oncogene Proteins; 0 / RUNX1 protein, human; 0 / Transcription Factors
  •  go-up   go-down


31. Issa JP, Garcia-Manero G, Giles FJ, Mannari R, Thomas D, Faderl S, Bayar E, Lyons J, Rosenfeld CS, Cortes J, Kantarjian HM: Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies. Blood; 2004 Mar 1;103(5):1635-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies.
  • A total of 50 patients were treated (44 with acute myelogenous leukemia [AML]/myelodysplasia [MDS], 5 with chronic myelogenous leukemia [CML], and 1 with acute lymphocytic leukemia [ALL]), and the drug was well tolerated at all dose levels, with myelosuppression being the major side effect.
  • We conclude that decitabine is effective in myeloid malignancies, and low doses are as or more effective than higher doses.
  • [MeSH-major] Antimetabolites, Antineoplastic / pharmacology. Azacitidine / analogs & derivatives. Azacitidine / therapeutic use. Hematologic Neoplasms / drug therapy. Leukemia / drug therapy. Myeloproliferative Disorders / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Cell Cycle Proteins / genetics. Cell Differentiation. Child. Child, Preschool. Cohort Studies. Cyclin-Dependent Kinase Inhibitor p15. DNA Methylation. DNA Modification Methylases / metabolism. Dose-Response Relationship, Drug. Female. Gene Silencing. Humans. Karyotyping. Male. Methylation. Middle Aged. Time Factors. Treatment Outcome. Tumor Suppressor Proteins / genetics

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. AZACITIDINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14604977.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / CDKN2B protein, human; 0 / Cell Cycle Proteins; 0 / Cyclin-Dependent Kinase Inhibitor p15; 0 / Tumor Suppressor Proteins; 776B62CQ27 / decitabine; EC 2.1.1.- / DNA Modification Methylases; M801H13NRU / Azacitidine
  •  go-up   go-down


32. Cohen MH, Johnson JR, Pazdur R: U.S. Food and Drug Administration Drug Approval Summary: conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approval. Clin Cancer Res; 2005 Jan 1;11(1):12-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] U.S. Food and Drug Administration Drug Approval Summary: conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approval.
  • Imatinib mesylate (Gleevec, Novartis Pharmaceuticals East Manruer, NJ) received accelerated approval on May 10, 2001 for the treatment of patients with chronic myeloid leukemia (CML) in (a) chronic phase after failure of IFN-alpha therapy, (b) accelerated phase, and (c) blast crisis.
  • The accelerated approval was accompanied by a postmarketing commitment by Novartis Pharmaceuticals to continue patient follow-up to determine duration of treatment response and survival.
  • Accelerated phase CML: Patients enrolled totaled 293: 235 with CML accelerated phase, 48 with relapsed/refractory acute lymphocytic leukemia, 2 with relapsed/refractory acute myelocytic leukemia, and 8 with relapsed/refractory CML in lymphoid blast crisis.
  • The median survival in the advanced leukemia population (acute lymphocytic leukemia, acute myelocytic leukemia, and lymphoid blast crisis) was only 5 months, and only two patients are still on treatment.
  • CONCLUSIONS: The results confirm those of the interim analysis and suggest that imatinib mesylate represents an effective therapeutic agent for the treatment of patients with CML in chronic phase after failure of IFN-alpha therapy, in blast crisis, and in accelerated phase.
  • [MeSH-major] Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Piperazines / pharmacology. Pyrimidines / pharmacology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Benzamides. Blast Crisis. Dose-Response Relationship, Drug. Drug Approval. Female. Humans. Imatinib Mesylate. Male. Middle Aged. Time Factors. Treatment Outcome. United States. United States Food and Drug Administration

  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15671523.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


33. Lee DG, Choi SM, Choi JH, Yoo JH, Park YH, Kim YJ, Lee S, Min CK, Kim HJ, Kim DW, Lee JW, Min WS, Shin WS, Kim CC: Selective bowel decontamination for the prevention of infection in acute myelogenous leukemia: a prospective randomized trial. Korean J Intern Med; 2002 Mar;17(1):38-44
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Selective bowel decontamination for the prevention of infection in acute myelogenous leukemia: a prospective randomized trial.
  • BACKGROUND: Infection is still a frequent cause of morbidity and mortality in acute myelogenous leukemia (AML) patients receiving chemotherapy.
  • METHODS: Ninety-five AML patients receiving chemotherapy at Catholic Hemopoietic Stem Cell Transplantation Center from March 1999 to July 1999 were randomly divided into the AP group (250 mg ciprofloxacin twice a day, 150 mg roxithromycin twice a day, 50 mg fluconazole once a day) and the control group for a prospective analysis.
  • CONCLUSION: The AP could not reduce the occurrence of infection or infection associated death in AML patients receiving chemotherapy.
  • [MeSH-major] Anti-Infective Agents / therapeutic use. Antibiotic Prophylaxis. Bacterial Infections / prevention & control. Ciprofloxacin / therapeutic use. Leukemia, Myeloid, Acute / complications. Neutropenia / complications
  • [MeSH-minor] Adult. Drug Therapy, Combination. Female. Fever / epidemiology. Fever / etiology. Fluconazole / therapeutic use. Humans. Incidence. Male. Middle Aged. Prospective Studies. Roxithromycin / therapeutic use. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Bacterial Infections.
  • Hazardous Substances Data Bank. CIPROFLOXACIN .
  • Hazardous Substances Data Bank. FLUCONAZOLE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12014211.001).
  • [ISSN] 1226-3303
  • [Journal-full-title] The Korean journal of internal medicine
  • [ISO-abbreviation] Korean J. Intern. Med.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Anti-Infective Agents; 21KOF230FA / Roxithromycin; 5E8K9I0O4U / Ciprofloxacin; 8VZV102JFY / Fluconazole
  • [Other-IDs] NLM/ PMC4531660
  •  go-up   go-down


34. Bonati A, Saglio G: [Molecular medicine: new tools for better understanding and treatment of diseases in humans]. Ann Ital Med Int; 2000 Jul-Sep;15(3):206-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Molecular medicine: new tools for better understanding and treatment of diseases in humans].
  • The authors discuss the importance that molecular medicine has assumed in recent years.
  • The importance of oncogenes, and their translocation in tumoral pathologies is emphasized, a case in point being the alterations observed in chronic myeloid leukemia and acute promyelocytic leukemia and their implication for innovative therapy.
  • [MeSH-minor] Acquired Immunodeficiency Syndrome / genetics. Adult. Aging / genetics. Alzheimer Disease / genetics. Cardiovascular Diseases / genetics. Central Nervous System Diseases / genetics. Colonic Neoplasms / genetics. DNA, Neoplasm / genetics. Endocrine System Diseases / genetics. Genetic Therapy. HIV Infections / genetics. Hepatitis C / genetics. Humans. Immunologic Deficiency Syndromes / therapy. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics. Leukemia, Promyelocytic, Acute / genetics. Mutation. Neoplasms / therapy. Research. Thromboembolism / genetics. Transcription, Genetic. Translocation, Genetic

  • HIV InSite. treatment guidelines - Cardiac Cardiac Manifestations of HIV .
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11059061.001).
  • [ISSN] 0393-9340
  • [Journal-full-title] Annali italiani di medicina interna : organo ufficiale della Società italiana di medicina interna
  • [ISO-abbreviation] Ann. Ital. Med. Int.
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] ITALY
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  • [Number-of-references] 61
  •  go-up   go-down


35. Thomas X, Raffoux E, Botton Sd, Pautas C, Arnaud P, de Revel T, Reman O, Terré C, Corront B, Gardin C, Le QH, Quesnel B, Cordonnier C, Bourhis JH, Elhamri M, Fenaux P, Preudhomme C, Michallet M, Castaigne S, Dombret H: Effect of priming with granulocyte-macrophage colony-stimulating factor in younger adults with newly diagnosed acute myeloid leukemia: a trial by the Acute Leukemia French Association (ALFA) Group. Leukemia; 2007 Mar;21(3):453-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of priming with granulocyte-macrophage colony-stimulating factor in younger adults with newly diagnosed acute myeloid leukemia: a trial by the Acute Leukemia French Association (ALFA) Group.
  • In a multicenter trial, 259 young adults (15-49 years) with newly diagnosed acute myeloid leukemia (AML) were first randomized to receive a timed-sequential induction regimen given either alone (135 patients) or concomitantly with granulocyte-macrophage colony-stimulating factor (GM-CSF) (124 patients).
  • Priming of leukemic cells with hematopoietic growth factors is a means of enhancing the efficacy of chemotherapy in younger adults with AML.
  • [MeSH-major] Granulocyte-Macrophage Colony-Stimulating Factor / pharmacology. Leukemia, Myeloid / drug therapy. Premedication
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Amsacrine / administration & dosage. Amsacrine / adverse effects. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cell Division / drug effects. Combined Modality Therapy. Cytarabine / administration & dosage. Cytarabine / adverse effects. Daunorubicin / administration & dosage. Daunorubicin / adverse effects. Disease-Free Survival. Drug Administration Schedule. Female. Hematopoietic Stem Cell Transplantation. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Mitoxantrone / administration & dosage. Mitoxantrone / adverse effects. Neoplastic Stem Cells / drug effects. Proportional Hazards Models. Recombinant Proteins / administration & dosage. Recombinant Proteins / pharmacology. Risk. Salvage Therapy. Stimulation, Chemical. Transplantation, Homologous. Treatment Outcome

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. AMSACRINE .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17252021.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Recombinant Proteins; 00DPD30SOY / Amsacrine; 04079A1RDZ / Cytarabine; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor; 99283-10-0 / molgramostim; BZ114NVM5P / Mitoxantrone; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


36. Keane FM, Munn SE, Buckley DA, Hopster D, Mufti GJ, du Vivier AW: Neutrophilic eccrine hidradenitis in two neutropaenic patients. Clin Exp Dermatol; 2001 Mar;26(2):162-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We describe two patients, who presented with erythematous facial plaques, in keeping with neutrophilic eccrine hidradenitis, during chemotherapy for acute myeloid leukaemia.
  • [MeSH-minor] Acute Disease. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cytarabine / administration & dosage. Daunorubicin / administration & dosage. Etoposide / administration & dosage. Female. Humans. Leukemia, Myeloid / complications. Leukemia, Myeloid / drug therapy. Mitoxantrone / administration & dosage

  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11298106.001).
  • [ISSN] 0307-6938
  • [Journal-full-title] Clinical and experimental dermatology
  • [ISO-abbreviation] Clin. Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; BZ114NVM5P / Mitoxantrone; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


37. Aljurf M, Al Qurashi F, Al Mohareb F, Sahovic E, Al Sharif F, Al Zahrani H, Al Shanqeeti A, Owaidah T, Iqbal A, Zaidi SZ, Nurgat ZA, Sanz M, Chaudhri N: High efficacy and low toxicity of APL induction with concurrent idarubicin/ATRA followed by a novel and simplified outpatient post-remission therapy using single doses of idarubicin and intermittent ATRA. Med Oncol; 2010 Sep;27(3):702-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Acute promyelocytic leukemia (APL) is one of the most curable myeloid malignancies because of its great sensitivity to all-trans retinoic acid (ATRA) and response to anthracycline therapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Promyelocytic, Acute / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Ambulatory Care. Clinical Trials as Topic / statistics & numerical data. Dexamethasone / administration & dosage. Disease-Free Survival. Drug Administration Schedule. Factor VIII / therapeutic use. Female. Fibrinogen / analysis. Fibrinogen / therapeutic use. Hemorrhage / chemically induced. Hemorrhage / drug therapy. Humans. Idarubicin / administration & dosage. Idarubicin / adverse effects. Kaplan-Meier Estimate. Male. Middle Aged. Pilot Projects. Remission Induction. Tretinoin / administration & dosage. Tretinoin / adverse effects. Young Adult

  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1992 Nov 1;80(9):2176-81 [1421389.001]
  • [Cites] Blood. 1991 Sep 15;78(6):1413-9 [1884013.001]
  • [Cites] Blood. 1995 Sep 1;86(5):1717-28 [7655004.001]
  • [Cites] Blood. 1993 Dec 1;82(11):3241-9 [8241496.001]
  • [Cites] Blood. 1999 Nov 1;94(9):3015-21 [10556184.001]
  • [Cites] Leukemia. 1993 Nov;7(11):1722-7 [8231241.001]
  • [Cites] Blood. 2004 Feb 15;103(4):1237-43 [14576047.001]
  • [Cites] Blood. 2010 Oct 28;116(17):3171-9 [20644121.001]
  • [Cites] Blood. 2005 Apr 15;105(8):3019-25 [15604216.001]
  • [Cites] J Clin Oncol. 1997 Feb;15(2):483-90 [9053469.001]
  • [Cites] Blood. 2002 Nov 1;100(9):3141-6 [12384411.001]
  • [Cites] Nouv Rev Fr Hematol. 1984;26(6):371-8 [6597407.001]
  • [Cites] Blood. 1997 Aug 1;90(3):1014-21 [9242531.001]
  • [Cites] J Clin Oncol. 1997 Nov;15(11):3330-7 [9363862.001]
  • [Cites] Blood. 2000 Aug 15;96(4):1247-53 [10942364.001]
  • [Cites] Haematologica. 1987 Mar-Apr;72(2):151-5 [3114070.001]
  • [Cites] N Engl J Med. 1997 Oct 9;337(15):1021-8 [9321529.001]
  • [Cites] Semin Hematol. 2004 Apr;41(2 Suppl 4):27-32 [15190513.001]
  • [Cites] Blood. 1995 Mar 1;85(5):1202-6 [7858250.001]
  • (PMID = 19669610.001).
  • [ISSN] 1559-131X
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / cryoprecipitate coagulum; 5688UTC01R / Tretinoin; 7S5I7G3JQL / Dexamethasone; 9001-27-8 / Factor VIII; 9001-32-5 / Fibrinogen; ZRP63D75JW / Idarubicin
  •  go-up   go-down


38. Sherman V, Reed J, Hollowood K, Littlewood T, Burge SM: Poromas and porokeratosis in a patient treated for solid-organ and haematological malignancies. Clin Exp Dermatol; 2010 Jun;35(4):e130-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We describe a patient with previous solid-organ (testicular, oesophageal) and haematological (acute myeloid leukaemia) malignancies, in whom chronic cutaneous graft-versus-host disease was complicated by poromas and porokeratosis.
  • [MeSH-minor] Adult. Graft vs Host Disease / complications. Humans. Leukemia, Myeloid, Acute / drug therapy. Male. Teratoma / therapy. Testicular Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19958368.001).
  • [ISSN] 1365-2230
  • [Journal-full-title] Clinical and experimental dermatology
  • [ISO-abbreviation] Clin. Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


39. Braess J, Fiegl M, Lorenz I, Waxenberger K, Hiddemann W: Modeling the pharmacodynamics of highly schedule-dependent agents: exemplified by cytarabine-based regimens in acute myeloid leukemia. Clin Cancer Res; 2005 Oct 15;11(20):7415-25
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Modeling the pharmacodynamics of highly schedule-dependent agents: exemplified by cytarabine-based regimens in acute myeloid leukemia.
  • BACKGROUND: Many agents in antineoplastic chemotherapy are highly schedule dependent.
  • N was to be numerically derived from a multitude of in vitro isoeffect analyses of the major agents in acute myeloid leukemia (AML) therapy from patient samples (n = 57).
  • CONCLUSION: The N-AUC concept is able to characterize schedule-dependent agents and is the only descriptor of cytarabine treatment strength actually correlated to the clinical effect in AML.
  • [MeSH-major] Cytarabine / pharmacokinetics. Leukemia, Myeloid / metabolism. Models, Biological
  • [MeSH-minor] Acute Disease. Adult. Algorithms. Antimetabolites, Antineoplastic / pharmacokinetics. Antimetabolites, Antineoplastic / pharmacology. Area Under Curve. Bone Marrow Cells / drug effects. Bone Marrow Cells / metabolism. Bone Marrow Cells / pathology. Cell Survival / drug effects. Dose-Response Relationship, Drug. Humans. Meta-Analysis as Topic. Randomized Controlled Trials as Topic

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16243815.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 04079A1RDZ / Cytarabine
  •  go-up   go-down


40. Chemaly RF, Fox SB, Alkotob LM, Scharpf J, Sobecks R, Eliachar I, Procop GW, Smith M, Avery RK, Schmitt SK: A case of zygomycosis and invasive candidiasis involving the epiglottis and tongue in an immunocompromised patient. Scand J Infect Dis; 2002;34(2):149-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We describe an unusual case of concomitant invasive candidiasis and zygomycosis of the tongue and epiglottis that occurred in a young patient with neutropenia during chemotherapy for acute myelogenous leukemia and was successfully treated medically.
  • [MeSH-major] Candidiasis / complications. Epiglottis / microbiology. Immunocompromised Host. Leukemia, Myeloid, Acute / complications. Tongue / microbiology. Zygomycosis / complications
  • [MeSH-minor] Adult. Amphotericin B / administration & dosage. Amphotericin B / therapeutic use. Antifungal Agents / administration & dosage. Antifungal Agents / therapeutic use. Antineoplastic Agents / adverse effects. Candida / isolation & purification. Cytarabine / adverse effects. Fungi / isolation & purification. Humans. Idarubicin / adverse effects. Male. Neutropenia / complications. Tongue Diseases / complications. Tongue Diseases / drug therapy. Tongue Diseases / microbiology

  • Genetic Alliance. consumer health - Zygomycosis.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Yeast Infections.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. AMPHOTERICIN B .
  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11928855.001).
  • [ISSN] 0036-5548
  • [Journal-full-title] Scandinavian journal of infectious diseases
  • [ISO-abbreviation] Scand. J. Infect. Dis.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Sweden
  • [Chemical-registry-number] 0 / Antifungal Agents; 0 / Antineoplastic Agents; 04079A1RDZ / Cytarabine; 7XU7A7DROE / Amphotericin B; ZRP63D75JW / Idarubicin
  •  go-up   go-down


41. Yang L, Dong ZR, Pan L, Luo JM, Xu SR: [Expression of midkine in patients with acute myeloid leukemia and its significance]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Jun;14(3):442-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of midkine in patients with acute myeloid leukemia and its significance].
  • The study was aimed to investigate the expression of midkine (MK) in bone marrow mononuclear cells (BM MNC) from 65 acute myeloid leukemia patients and 15 normal controls.
  • The results showed that the expression of MK of BM MNCs in 50 newly diagnosed AML patients (0.331 +/- 0.436) and 15 AML patients in relapse (0.374 +/- 0.463) were markedly higher than that in 15 CR cases (0.067 +/- 0.190), and 15 normal controls (0), respectively.
  • The positive rate of MK gene expression in drug-resistant patients and drug-sensitive patients were 57.69% and 25.64% respectively and there was positive correlation between the gene expressions of MK and bcl-2 (P < 0.01) (r = 0.0556, P < 0.001).
  • It is concluded that MK can be secreted by AML cells and involved in drug-resistant, its positive expression may be associated with the poor prognosis in newly diagnosed AML patients.

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16800916.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Cytokines; 0 / RNA, Messenger; 137497-38-2 / midkine
  •  go-up   go-down


42. Roboz GJ, Giles FJ, Ritchie EK, Allen-Bard S, Curcio TJ, Wilkes MA, Park SL, Kantarjian HM, Faderl S, Ravandi F, Kelner MJ, Feldman EJ: Phase I/II study of continuous-infusion troxacitabine in refractory acute myeloid leukemia. J Clin Oncol; 2007 Jan 1;25(1):10-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I/II study of continuous-infusion troxacitabine in refractory acute myeloid leukemia.
  • PURPOSE: Troxacitabine is a non-natural nucleoside analog with unique structural and metabolic features.
  • Bolus intravenous (IV) troxacitabine regimens have shown significant activity in patients with refractory acute myeloid leukemia (AML) and preclinical data suggest that administration via continuous infusion may result in enhanced antitumor activity.
  • PATIENTS AND METHODS: Patients with refractory AML initially received troxacitabine 10.1 mg/m2 by continuous IV infusion (CIVI) for 48 hours.
  • All patients responding to troxacitabine had steady-state serum drug concentration of more than approximately 80 ng/mL.
  • CONCLUSION: Troxacitabine administered as a CIVI allows a significant increase in dose-intensity in comparison to IV bolus regimens, has antileukemic activity, and warrants additional investigation in patients with refractory AML.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Antineoplastic Agents / pharmacokinetics. Cytosine / analogs & derivatives. Dioxolanes / administration & dosage. Dioxolanes / pharmacokinetics. Leukemia, Myeloid, Acute / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Humans. Infusions, Intravenous. Male. Middle Aged. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2007 Jan 1;25(1):1-2 [17146103.001]
  • (PMID = 17146106.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Dioxolanes; 60KQZ0388Y / troxacitabine; 8J337D1HZY / Cytosine
  •  go-up   go-down


43. Cornely OA, Maertens J, Winston DJ, Perfect J, Ullmann AJ, Walsh TJ, Helfgott D, Holowiecki J, Stockelberg D, Goh YT, Petrini M, Hardalo C, Suresh R, Angulo-Gonzalez D: Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med; 2007 Jan 25;356(4):348-59
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Patients with neutropenia resulting from chemotherapy for acute myelogenous leukemia or the myelodysplastic syndrome are at high risk for difficult-to-treat and often fatal invasive fungal infections.
  • Survival was significantly longer among recipients of posaconazole than among recipients of fluconazole or itraconazole (P=0.04).
  • CONCLUSIONS: In patients undergoing chemotherapy for acute myelogenous leukemia or the myelodysplastic syndrome, posaconazole prevented invasive fungal infections more effectively than did either fluconazole or itraconazole and improved overall survival.
  • [MeSH-major] Antifungal Agents / therapeutic use. Fluconazole / therapeutic use. Itraconazole / therapeutic use. Mycoses / prevention & control. Neutropenia / drug therapy. Opportunistic Infections / prevention & control. Triazoles / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antineoplastic Agents / adverse effects. Female. Humans. Kaplan-Meier Estimate. Leukemia, Myeloid, Acute / complications. Leukemia, Myeloid, Acute / drug therapy. Leukemia, Myeloid, Acute / mortality. Male. Middle Aged. Myelodysplastic Syndromes / complications. Myelodysplastic Syndromes / drug therapy. Myelodysplastic Syndromes / mortality. Single-Blind Method. Treatment Outcome


44. Wollina U, Sayer HG, Wollina K, Graefe T: Very late appearance of acute graft-versus-host disease after tapering immunosuppression. J Dermatol; 2001 Dec;28(12):734-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Very late appearance of acute graft-versus-host disease after tapering immunosuppression.
  • Here we report a 40-year-old woman who developed an acute GVHD 30 months after transplantation.
  • Late and very late appearance of acute GVHD has only been described in rare cases.
  • [MeSH-major] Graft vs Host Disease / diagnosis. Hand Dermatoses / diagnosis. Hematopoietic Stem Cell Transplantation. Immunosuppressive Agents / administration & dosage. Leukemia, Myeloid, Acute / therapy
  • [MeSH-minor] Adult. Diagnosis, Differential. Drug Administration Schedule. Female. Humans

  • Genetic Alliance. consumer health - Late acute graft versus host disease.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11804070.001).
  • [ISSN] 0385-2407
  • [Journal-full-title] The Journal of dermatology
  • [ISO-abbreviation] J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Immunosuppressive Agents
  •  go-up   go-down


45. Damaj G, Ivanov V, Le Brigand B, D'incan E, Doglio MF, Bilger K, Faucher C, Vey N, Gastaut JA: Rapid improvement of disseminated aspergillosis with caspofungin/voriconazole combination in an adult leukemic patient. Ann Hematol; 2004 Jun;83(6):390-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rapid improvement of disseminated aspergillosis with caspofungin/voriconazole combination in an adult leukemic patient.
  • A 57-year-old man with acute myeloid leukemia (AML) French-American-British (FAB) 4 developed disseminated invasive cerebral and pulmonary aspergillosis during postinduction aplasia.
  • [MeSH-major] Antifungal Agents / administration & dosage. Aspergillosis / drug therapy. Leukemia, Myelomonocytic, Acute / microbiology. Peptides / administration & dosage. Peptides, Cyclic. Pyrimidines / administration & dosage. Triazoles / administration & dosage
  • [MeSH-minor] Drug Therapy, Combination. Echinocandins. Humans. Male. Middle Aged. Treatment Outcome. Voriconazole

  • Genetic Alliance. consumer health - Aspergillosis.
  • MedlinePlus Health Information. consumer health - Aspergillosis.
  • Hazardous Substances Data Bank. CASPOFUNGIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14666380.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antifungal Agents; 0 / Echinocandins; 0 / Peptides; 0 / Peptides, Cyclic; 0 / Pyrimidines; 0 / Triazoles; F0XDI6ZL63 / caspofungin; JFU09I87TR / Voriconazole
  •  go-up   go-down


46. Okutsu J, Tsunoda T, Kaneta Y, Katagiri T, Kitahara O, Zembutsu H, Yanagawa R, Miyawaki S, Kuriyama K, Kubota N, Kimura Y, Kubo K, Yagasaki F, Higa T, Taguchi H, Tobita T, Akiyama H, Takeshita A, Wang YH, Motoji T, Ohno R, Nakamura Y: Prediction of chemosensitivity for patients with acute myeloid leukemia, according to expression levels of 28 genes selected by genome-wide complementary DNA microarray analysis. Mol Cancer Ther; 2002 Oct;1(12):1035-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prediction of chemosensitivity for patients with acute myeloid leukemia, according to expression levels of 28 genes selected by genome-wide complementary DNA microarray analysis.
  • To identify genes involved in the sensitivity of acute myeloid leukemia (AML) cells to chemotherapy, we monitored gene-expression profiles of cancer cells from 76 AML patients using a cDNA microarray consisting of 23,040 genes.
  • We identified 63 genes that were commonly overexpressed and 372 genes suppressed in AML.
  • Because these genes represent key molecules for disclosing the molecular mechanisms of AML, they may be potential targets for drug development.
  • On that basis, we developed a "Drug Response Scoring" system that was correlated well with individual sensitivity to an anticancer drug regimen.
  • Among the 44 cases with positive drug-response scores by our definition, 40 achieved complete remission after treatment, whereas the only 3 of the 20 cases with negative scores responded well to the treatment.
  • [MeSH-major] Genome. Leukemia, Myeloid, Acute / drug therapy. Leukemia, Myeloid, Acute / metabolism. Oligonucleotide Array Sequence Analysis
  • [MeSH-minor] Adult. Aged. DNA, Complementary / metabolism. Down-Regulation. Female. Humans. Male. Middle Aged. RNA / metabolism. Up-Regulation

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12481426.001).
  • [ISSN] 1535-7163
  • [Journal-full-title] Molecular cancer therapeutics
  • [ISO-abbreviation] Mol. Cancer Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Complementary; 63231-63-0 / RNA
  •  go-up   go-down


47. Mills KI, Gilkes AF: Clinical implications of gene expression profiling of acute myeloid leukemia. Curr Hematol Malig Rep; 2006 Jun;1(2):114-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical implications of gene expression profiling of acute myeloid leukemia.
  • Since the first demonstration in 1999 that gene expression profiling could distinguish between different variants of acute leukemia, several studies have analyzed patients with acute myeloid leukemia on the basis of cytogenetics, morphologic subgroups, secondary mutations such as FLT3, prognosis, and therapeutic response.
  • [MeSH-major] Gene Expression Profiling. Leukemia, Myeloid, Acute / genetics
  • [MeSH-minor] Adult. Child. Drug Resistance, Neoplasm / genetics. Gene Expression Regulation, Leukemic. Humans. Mutation. Neoplasm Proteins / genetics. Patient Selection. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Prognosis. Translocation, Genetic. Treatment Outcome

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 2005 Mar;19(3):402-9 [15674361.001]
  • [Cites] Blood. 2002 Oct 1;100(7):2292-302 [12239137.001]
  • [Cites] Genes Chromosomes Cancer. 2005 Jun;43(2):113-27 [15751046.001]
  • [Cites] Blood. 2004 Dec 1;104(12):3679-87 [15226186.001]
  • [Cites] Mol Cancer Ther. 2002 Oct;1(12):1035-42 [12481426.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jan 30;98(3):1124-9 [11158605.001]
  • [Cites] Blood. 2005 Nov 15;106(10):3618-20 [16046528.001]
  • [Cites] Br J Haematol. 1976 Aug;33(4):451-8 [188440.001]
  • [Cites] Blood. 2005 Aug 15;106(4):1189-98 [15878973.001]
  • [Cites] Blood. 2001 Sep 15;98(6):1752-9 [11535508.001]
  • [Cites] Oncogene. 2004 Dec 16;23(58):9381-91 [15543237.001]
  • [Cites] Genes Chromosomes Cancer. 2003 Jun;37(2):149-58 [12696063.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 May 14;99(10):6567-72 [12011421.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3768-76 [16105978.001]
  • [Cites] Blood. 2004 Nov 1;104(9):2646-54 [15251987.001]
  • [Cites] Genes Chromosomes Cancer. 2003 Aug;37(4):396-405 [12800151.001]
  • [Cites] Blood. 2003 Sep 1;102(5):1849-56 [12738660.001]
  • [Cites] Br J Haematol. 2005 Jul;130(2):203-8 [16029448.001]
  • [Cites] Blood. 1998 Oct 1;92(7):2322-33 [9746770.001]
  • [Cites] Oncogene. 2005 Feb 24;24(9):1580-8 [15674343.001]
  • [Cites] Genes Chromosomes Cancer. 2003 May;37(1):72-8 [12661007.001]
  • [Cites] Blood. 2005 Sep 15;106(6):2113-9 [15951308.001]
  • [Cites] Eur J Haematol. 2005 Sep;75(3):185-92 [16104873.001]
  • [Cites] Genes Chromosomes Cancer. 2005 Mar;42(3):299-307 [15609343.001]
  • [Cites] Blood. 2005 Aug 1;106(3):899-902 [15831697.001]
  • [Cites] Genes Chromosomes Cancer. 2003 Jul;37(3):237-51 [12759922.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3733-9 [16076867.001]
  • [Cites] Int J Oncol. 2003 Sep;23 (3):617-25 [12888896.001]
  • [Cites] J Clin Oncol. 2004 Feb 15;22(4):624-33 [14726504.001]
  • [Cites] N Engl J Med. 2004 Apr 15;350(16):1617-28 [15084694.001]
  • [Cites] Blood. 2005 Aug 15;106(4):1419-22 [15870172.001]
  • [Cites] Leuk Res. 2003 Feb;27(2):125-31 [12526918.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5116-21 [11309499.001]
  • [Cites] Haematologica. 2003 Jan;88(1):19-24 [12551822.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jul 23;99(15):10008-13 [12105272.001]
  • [Cites] N Engl J Med. 2004 Apr 15;350(16):1605-16 [15084693.001]
  • [Cites] Science. 1999 Oct 15;286(5439):531-7 [10521349.001]
  • (PMID = 20425341.001).
  • [ISSN] 1558-822X
  • [Journal-full-title] Current hematologic malignancy reports
  • [ISO-abbreviation] Curr Hematol Malig Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neoplasm Proteins
  • [Number-of-references] 39
  •  go-up   go-down


48. Stalfelt AM, Brodin H, Pettersson S, Eklöf A: The final phase in acute myeloid leukaemia (AML). A study on bleeding, infection and pain. Leuk Res; 2003 Jun;27(6):481-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The final phase in acute myeloid leukaemia (AML). A study on bleeding, infection and pain.
  • To increase the knowledge of the final phase of acute myeloid leukaemia (AML) a retrospective review of the medical and nursing records of 106 adult patients with AML who had died in 1995-1997 was made.
  • To give AML patients in the final phase, the best possible treatment, skills in palliative medicine and palliative care are important.
  • [MeSH-major] Hemorrhage / physiopathology. Infection / physiopathology. Leukemia, Myeloid / drug therapy. Leukemia, Myeloid / physiopathology. Pain / physiopathology. Palliative Care / methods
  • [MeSH-minor] Acute Disease. Aged. Aged, 80 and over. Analgesics, Opioid / therapeutic use. Attitude to Death. Cause of Death. Female. Humans. Male. Middle Aged. Morphine / therapeutic use. Quality of Life. Retrospective Studies. Terminal Care / methods

  • MedlinePlus Health Information. consumer health - Bleeding.
  • MedlinePlus Health Information. consumer health - Pain.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • Hazardous Substances Data Bank. MORPHINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12648506.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Analgesics, Opioid; 76I7G6D29C / Morphine
  •  go-up   go-down


49. Quartino A, Karlsson MO, Freijs A, Jonsson N, Nygren P, Kristensen J, Lindhagen E, Larsson R: Modeling of in vitro drug activity and prediction of clinical outcome in acute myeloid leukemia. J Clin Pharmacol; 2007 Aug;47(8):1014-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Modeling of in vitro drug activity and prediction of clinical outcome in acute myeloid leukemia.
  • The objectives of this study were to develop a population pharmacodynamic model describing the in vitro drug sensitivity of tumor cells and to relate in vitro parameters to clinical outcome.
  • Cell samples from 179 patients with acute myelocytic leukemia were exposed to cytosine arabinoside and daunorubicin, and cytotoxicity was analyzed using the fluorometric microculture cytotoxicity assay.
  • The model predicted drug potency (EC(50)) adequately from 1 concentration measurement.
  • A logistic regression on individual in vitro parameters of 46 patients treated with the daunorubicin plus cytosine arabinoside regimen showed that the probability of complete response was significantly (P < .05) related to the product of the E(max)/EC(50) ratio of the two drugs.
  • The findings demonstrate the value of population pharmacodynamic modeling of in vitro drug sensitivity data and a significant relationship between the in vitro parameters and clinical outcome.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Myeloid / drug therapy
  • [MeSH-minor] Acute Disease. Adult. Cell Survival / drug effects. Cytarabine / administration & dosage. Daunorubicin / administration & dosage. Humans. In Vitro Techniques. Models, Biological. Nonlinear Dynamics. Prognosis. Retrospective Studies. Spectrometry, Fluorescence. Treatment Outcome. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17660484.001).
  • [ISSN] 0091-2700
  • [Journal-full-title] Journal of clinical pharmacology
  • [ISO-abbreviation] J Clin Pharmacol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


50. Smith KJ, Welsh M, Skelton H: Trichophyton rubrum showing deep dermal invasion directly from the epidermis in immunosuppressed patients. Br J Dermatol; 2001 Aug;145(2):344-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We present three patients with acute leukaemias, with ill-defined pre-existent cutaneous eruptions that were treated with a potent topical corticosteroid.
  • [MeSH-minor] Adolescent. Adult. Amphotericin B / therapeutic use. Anti-Inflammatory Agents / therapeutic use. Antifungal Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Fluconazole / therapeutic use. Humans. Leukemia, Myeloid, Acute / drug therapy. Leukemia, Myeloid, Acute / immunology. Leukemia, Promyelocytic, Acute / drug therapy. Leukemia, Promyelocytic, Acute / immunology. Male. Middle Aged. Naphthalenes / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology. Steroids. Treatment Outcome. Trichophyton / immunology

  • MedlinePlus Health Information. consumer health - Tinea Infections.
  • Hazardous Substances Data Bank. AMPHOTERICIN B .
  • Hazardous Substances Data Bank. FLUCONAZOLE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11531807.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Antifungal Agents; 0 / Naphthalenes; 0 / Steroids; 7XU7A7DROE / Amphotericin B; 8VZV102JFY / Fluconazole; G7RIW8S0XP / terbinafine
  •  go-up   go-down


51. Paietta E, Ferrando AA, Neuberg D, Bennett JM, Racevskis J, Lazarus H, Dewald G, Rowe JM, Wiernik PH, Tallman MS, Look AT: Activating FLT3 mutations in CD117/KIT(+) T-cell acute lymphoblastic leukemias. Blood; 2004 Jul 15;104(2):558-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Activating FLT3 mutations in CD117/KIT(+) T-cell acute lymphoblastic leukemias.
  • Activating FLT3 mutations are the most common genetic aberrations in acute myeloid leukemia (AML), resulting in the constitutive activation of this receptor tyrosine kinase (RTK), but such mutations are rarely found in acute lymphoblastic leukemia (ALL).
  • Here we describe a unique subset of de novo adult T-cell ALL (T-ALL) cases that coexpress CD117/KIT and cytoplasmic CD3 (CD117/KIT(+) ALL).
  • Activating mutations in the FLT3 RTK gene were found in each of 3 CD117/KIT(+) cases that were analyzed, but not in 52 other adult T-ALL samples from the same series that lacked CD117/KIT expression.
  • Our results indicate the need for clinical trials to test the efficacy of drugs that inhibit the FLT3 RTK in this subset of patients with T-ALL.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / physiopathology. Proto-Oncogene Proteins / genetics. Proto-Oncogene Proteins / metabolism. Proto-Oncogene Proteins c-kit / genetics. Proto-Oncogene Proteins c-kit / metabolism. Receptor Protein-Tyrosine Kinases / genetics. Receptor Protein-Tyrosine Kinases / metabolism

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Blood. 2005 Dec 15;106(13):4414-5 [16326981.001]
  • (PMID = 15044257.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA11083; United States / NCI NIH HHS / CA / CA21115; United States / NCI NIH HHS / CA / CA23318; United States / NCI NIH HHS / CA / CA56771; United States / NCI NIH HHS / CA / CA68484
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins; EC 2.7.10.1 / FLT3 protein, human; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3
  •  go-up   go-down


52. Leleu X, Soumerai J, Roccaro A, Hatjiharissi E, Hunter ZR, Manning R, Ciccarelli BT, Sacco A, Ioakimidis L, Adamia S, Moreau AS, Patterson CJ, Ghobrial IM, Treon SP: Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenström macroglobulinemia treated with nucleoside analogs. J Clin Oncol; 2009 Jan 10;27(2):250-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenström macroglobulinemia treated with nucleoside analogs.
  • PURPOSE: Nucleoside analogs (NAs) are considered as appropriate agents in the treatment of Waldenström macroglobulinemia (WM), a lymphoplasmacytic lymphoma.
  • Sporadic reports on increased incidence of transformation to high-grade non-Hodgkin's lymphoma and development of therapy-related myelodysplasia/acute leukemia (t-MDS/AML) among patients with WM treated with NAs prompted us to examine the incidence of such events in a large population of patients with WM.
  • RESULTS: Overall, 12 patients (6.2%) either developed transformation (n = 9; 4.7%) or developed t-MDS/AML (n = 3; 1.6%) among NA-treated patients, compared with one patient (0.4%) who developed transformation in the non-NA treated group (P < .001); no such events occurred among untreated patients.
  • Transformation and t-MDS/AML occurred at a median of 5 years from onset of NA therapy.
  • However, all NA-treated patients who developed t-MDS/AML died at a median of 5 months.
  • CONCLUSION: These data demonstrate an increased incidence of disease transformation to high-grade NHL and the development of t-MDS/AML among patients with WM treated with NAs.
  • [MeSH-major] Cell Transformation, Neoplastic / pathology. Leukemia, Myeloid, Acute / pathology. Myelodysplastic Syndromes / pathology. Nucleosides / therapeutic use. Waldenstrom Macroglobulinemia / drug therapy. Waldenstrom Macroglobulinemia / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chlorambucil / therapeutic use. Cladribine / therapeutic use. Female. Follow-Up Studies. Humans. Incidence. Lymphoma, Non-Hodgkin / epidemiology. Lymphoma, Non-Hodgkin / pathology. Male. Middle Aged. Retrospective Studies. Vidarabine / analogs & derivatives. Vidarabine / therapeutic use


53. Tallman MS: Therapy of acute myeloid leukemia. Cancer Control; 2001 Jan-Feb;8(1):62-78
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapy of acute myeloid leukemia.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Myeloid, Acute / drug therapy
  • [MeSH-minor] Adult. Age Factors. Aged. Bone Marrow Transplantation. Cytarabine / administration & dosage. Dose-Response Relationship, Drug. Female. Growth Substances / therapeutic use. Humans. Male. Middle Aged. Randomized Controlled Trials as Topic. Remission Induction

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11176038.001).
  • [ISSN] 1073-2748
  • [Journal-full-title] Cancer control : journal of the Moffitt Cancer Center
  • [ISO-abbreviation] Cancer Control
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Growth Substances; 04079A1RDZ / Cytarabine
  • [Number-of-references] 122
  •  go-up   go-down


54. Lin PC, Poh SB, Lee MY, Hsiao LT, Chen PM, Chiou TJ: Fatal fulminant hepatitis B after withdrawal of prophylactic lamivudine in hematopoietic stem cell transplantation patients. Int J Hematol; 2005 May;81(4):349-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hepatitis B virus (HBV) reactivation can give rise to acute hepatitis and even fatal fulminant hepatitis in patients receiving immunosuppressive or cytostatic treatment.
  • One patient with non-Hodgkin's lymphoma completed 6 courses of CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine [Oncovin], and prednisone) and autologous peripheral blood SCT (PBSCT).
  • The second patient had acute myeloid leukemia.
  • We suggest that the duration of prophylactic use of lamivudine in chronic HBV carriers receiving HSCT be prolonged until the patient's immune system has been reconstituted.
  • [MeSH-major] Anti-HIV Agents / administration & dosage. Hematopoietic Stem Cell Transplantation. Hepatitis B / etiology. Lamivudine / administration & dosage. Liver Failure, Acute / etiology
  • [MeSH-minor] Acute Disease. Adult. Fatal Outcome. Female. Humans. Leukemia, Myeloid / drug therapy. Lymphoma, Non-Hodgkin / drug therapy. Male


55. Mukiibi JM, Nyirenda CM, Adewuyi JO, Mzula EL, Magombo ED, Mbvundula EM: Leukaemia at Queen Elizabeth Central Hospital in Blantyre, Malawi. East Afr Med J; 2001 Jul;78(7):349-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • An overview of the problems encountered in the management of leukaemia in developing countries especially those in sub-Saharan Africa are highlighted.
  • The main leukaemia types were: acute lymphoblastic leukaemia (ALL) 14 (14.7%), acute myeloblastic leukaemia (AML) 25 (26.3%), chronic myeloid (granulocytic) leukaemia (CML) 32 (33.7%), chronic lymphocytic (lymphatic) leukaemia (CLL) 22 (23.2%) and hairy cell leukaemia (HCL) two (2.1%) patients.
  • Most of the acute leukaemia (AL) cases occurred in the six to 15 year age bracket with a male preponderance.
  • In ALL, lymphadenopathy was the commonest presenting feature followed by pallor (92.9%) while in the AML group, pallor occurred in 80% of cases.
  • Haematologically, although leucocytosis characterised both acute and chronic leukaemias, most cases of acute leukaemia presented with more severe anaemia (Hb < 7 g/dl) and marked thrombocytopenia (Platelet count < 50 x 10(9)/l) than the chronic leukaemias.
  • While there is need to increase diagnostic awareness among clinicians and laboratory staff, the severe chronic shortage of cytotoxic drugs and lack of supportive care facilities commonly encountered in developing countries should be realistically addressed through cost-sharing, cost recovery, adequate government subvention and donations from charitable organisations.
  • [MeSH-major] Leukemia / epidemiology
  • [MeSH-minor] Adolescent. Adult. Africa, Eastern / epidemiology. Age Distribution. Child. Developing Countries. Female. Humans. Male. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11957257.001).
  • [ISSN] 0012-835X
  • [Journal-full-title] East African medical journal
  • [ISO-abbreviation] East Afr Med J
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Kenya
  • [Number-of-references] 18
  •  go-up   go-down


56. Ferrara F, Palmieri S, De Simone M, Sagristani M, Viola A, Pocali B, Fasanaro A, Mele G: High-dose idarubicin and busulphan as conditioning to autologous stem cell transplantation in adult patients with acute myeloid leukaemia. Br J Haematol; 2005 Jan;128(2):234-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose idarubicin and busulphan as conditioning to autologous stem cell transplantation in adult patients with acute myeloid leukaemia.
  • Between 30 and 50% of patients with acute myeloid leukaemia (AML) relapse after autologous stem cell transplantation (ASCT).
  • One possibility of reducing the relapse rate could be the adoption of conditioning regimens specifically designed for AML.
  • All patients had non-M3-AML and were in first complete remission (CR).
  • Our data show that a conditioning regimen based on high-dose IDA plus busulphan results in an encouraging reduction of the relapse rate after ASCT in AML.
  • [MeSH-major] Busulfan / therapeutic use. Idarubicin / therapeutic use. Immunosuppressive Agents / therapeutic use. Leukemia, Myeloid / surgery. Stem Cell Transplantation. Transplantation Conditioning / methods
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Drug Administration Schedule. Female. Follow-Up Studies. Humans. Male. Middle Aged. Survival Analysis. Transplantation, Autologous

  • Genetic Alliance. consumer health - Transplantation.
  • Hazardous Substances Data Bank. BUSULFAN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15638859.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; G1LN9045DK / Busulfan; ZRP63D75JW / Idarubicin
  •  go-up   go-down


57. Visani G, Olivieri A, Malagola M, Brunori M, Piccaluga PP, Capelli D, Pomponio G, Martinelli G, Isidori A, Sparaventi G, Leoni P: Consolidation therapy for adult acute myeloid leukemia: a systematic analysis according to evidence based medicine. Leuk Lymphoma; 2006 Jun;47(6):1091-102
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Consolidation therapy for adult acute myeloid leukemia: a systematic analysis according to evidence based medicine.
  • Post-remission therapy in acute myeloid leukemia (AML) remains problematic.
  • The purpose of our study was to identify the most important randomized and controlled studies comparing these three therapeutic options, in order to draw conclusions and possible suggestions for post-remission therapy of AML, according to the evidence based medicine (EBM) rules.
  • We searched the MEDLINE computer database for reports from 1985 through January 2005 and selected for analysis the clinical trials conducted over adults affected by newly diagnosed AML aged less than 65 years.
  • Overall we found 7750 papers; by using the limits "clinical trial" as publication type, "all adults 19+ years", we were able to select 344 papers.
  • 1) is auto-SCT superior to ICC/no other therapy in improving DFS and/or OS in adult AML patients in first CR?
  • 2) is allo-SCT superior to auto-SCT/other therapeutic options in improving DFS and/or OS in adult AML patients in first CR?
  • Moreover, the scarce data concerning the comparison between auto-SCT and chemotherapy in different subsets of patients are unable to suggest a differentiated approach in patients with high-risk, standard-risk or low-risk AML.
  • Concerning the second query, interpretation of data from the main prospective studies about the role of allo-SCT in previously untreated AML is not easy.
  • The first problem is the lack of real randomized clinical trials; in fact, according to the reported studies, AML patients generally receive allo-SCT on the basis of donor availability (the so called "genetic randomization").
  • The second problem is the frequent absence of intention to treat analysis.
  • In conclusion, the EBM approach highlighted the limitations observed in the published studies concerning consolidation therapy in AML; some suggestions, emerging from non-randomized, as well as randomized studies, are adequate, but not conclusive.
  • This point, coupled with the intrinsic complexity to study AML biological heterogeneity, is probably a major obstacle to draw conclusive evidences for consolidation therapy in AML.
  • These observations should plan to address new randomized studies on AML therapy; however, due to the emergence of genetic subgroups and new drugs targeting specific abnormalities, these trials should probably be designed directly focusing on the single entities.
  • In this way, the cure of AML could eventually become the cure of each specific AML subset with its peculiar biological, molecular and prognostic features.
  • [MeSH-major] Evidence-Based Medicine. Leukemia, Myeloid, Acute / drug therapy. Stem Cell Transplantation / methods
  • [MeSH-minor] Adult. Age Factors. Antineoplastic Agents / pharmacology. Clinical Trials as Topic / methods. Disease-Free Survival. Humans. Remission Induction. Research Design. Transplantation, Homologous. Treatment Outcome


58. Schultz KA, Chen L, Chen Z, Zeltzer LK, Nicholson HS, Neglia JP: Health and risk behaviors in survivors of childhood acute myeloid leukemia: a report from the Children's Oncology Group. Pediatr Blood Cancer; 2010 Jul 15;55(1):157-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Health and risk behaviors in survivors of childhood acute myeloid leukemia: a report from the Children's Oncology Group.
  • BACKGROUND: Survivors of childhood acute myeloid leukemia (AML) face increased risks of chronic disease and secondary malignancies.
  • Substance exposure may compound these risks.
  • PROCEDURES: Participants were diagnosed with AML at <21 years of age and survived > or =5 years following diagnosis.
  • Of the substance exposures assessed by YRBS, tobacco, alcohol, and marijuana were most common.
  • Men were more likely to report high substance exposure (P = 0.004).
  • CONCLUSIONS: This analysis reveals exposure to tobacco, alcohol, and marijuana in young adults with few differences based on treatment received.

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Childhood.
  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncol Nurs Forum. 1999 Oct;26(9):1475-86 [11064879.001]
  • [Cites] Drug Alcohol Depend. 2008 Nov 1;98(1-2):13-23 [18585871.001]
  • [Cites] J Clin Oncol. 2001 Jul 1;19(13):3163-72 [11432882.001]
  • [Cites] Med Pediatr Oncol. 2001 Jul;37(1):42-6 [11466722.001]
  • [Cites] Med Pediatr Oncol. 2002 Apr;38(4):229-39 [11920786.001]
  • [Cites] J Clin Oncol. 2003 Jan 15;21(2):189-96 [12525509.001]
  • [Cites] JAMA. 2003 Sep 24;290(12):1583-92 [14506117.001]
  • [Cites] Ann Intern Med. 2004 Apr 6;140(7):557-68 [15068985.001]
  • [Cites] Semin Oncol. 1982 Mar;9(1):34-51 [6176027.001]
  • [Cites] J Clin Oncol. 1993 Aug;11(8):1448-57 [8336184.001]
  • [Cites] J Clin Oncol. 1994 Jan;12(1):127-35 [8270968.001]
  • [Cites] J Natl Cancer Inst. 1994 Jan 19;86(2):131-7 [8271296.001]
  • [Cites] J Clin Oncol. 1994 Nov;12(11):2367-77 [7964952.001]
  • [Cites] Blood. 1996 Jun 15;87(12):4979-89 [8652810.001]
  • [Cites] J Natl Cancer Inst. 1998 Feb 4;90(3):219-25 [9462679.001]
  • [Cites] Ann Epidemiol. 2005 Mar;15(3):202-6 [15723765.001]
  • [Cites] J Clin Oncol. 2005 Sep 20;23(27):6516-23 [16116148.001]
  • [Cites] Semin Hematol. 2006 Jan;43(1):42-52 [16412788.001]
  • [Cites] J Clin Oncol. 2006 Jan 20;24(3):476-83 [16421424.001]
  • [Cites] Pediatr Blood Cancer. 2006 May 1;46(5):565-9 [16261562.001]
  • [Cites] Prev Med. 2006 Jun;42(6):435-42 [16626797.001]
  • [Cites] Cancer. 2006 Sep 15;107(6):1303-12 [16894525.001]
  • [Cites] N Engl J Med. 2006 Oct 12;355(15):1572-82 [17035650.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 2007 Nov 9;56(44):1157-61 [17989644.001]
  • [Cites] Cancer. 2008 May 1;112(9):2071-9 [18327823.001]
  • [Cites] J Natl Cancer Inst. 2001 Apr 18;93(8):618-29 [11309438.001]
  • (PMID = 20232426.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U24 CA055727; United States / NCI NIH HHS / CA / U10 CA98413; United States / NCI NIH HHS / CA / 5U10CA78960; United States / NCI NIH HHS / CA / U24 CA55727; United States / NCI NIH HHS / CA / U10 CA007306-39; United States / NCI NIH HHS / CA / U10 CA098413; United States / NCI NIH HHS / CA / U10 CA098543-08; None / None / / U10 CA098543-08; United States / NCI NIH HHS / CA / U10 CA098543; United States / NCI NIH HHS / CA / CA078960-04; United States / NCI NIH HHS / CA / CA007306-39; United States / NCI NIH HHS / CA / U10 CA098413-08; None / None / / U10 CA098413-08; United States / NCI NIH HHS / CA / U10 CA98543; United States / NCI NIH HHS / CA / 5U10 CA07306; United States / NCI NIH HHS / CA / R01 CA078960-04
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS166508; NLM/ PMC3152207
  •  go-up   go-down


59. Tallman MS, Gilliland DG, Rowe JM: Drug therapy for acute myeloid leukemia. Blood; 2005 Aug 15;106(4):1154-63
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Drug therapy for acute myeloid leukemia.
  • Although improvement in outcomes has occurred in younger adults with acute myeloid leukemia (AML) during the past 4 decades, progress in older adults has been much less conspicuous, if at all.
  • Approximately 50% to 75% of adults with AML achieve complete remission (CR) with cytarabine and an anthracycline such as daunorubicin or idarubicin or the anthracenedione mitoxantrone.
  • A variety of prognostic factors can predict outcome and include the karyotype of the leukemic cells and the presence of transmembrane transporter proteins, which extrude certain chemotherapy agents from the cell and confer multidrug resistance and mutations in or over expressions of specific genes such as WT1, CEBPA, BAX and the ratio of BCL2 to BAX, BAALC, EVI1, KIT, and FLT3.
  • Most recently, insights into the molecular pathogenesis of AML have led to the development of more specific targeted agents and have ushered in an exciting new era of antileukemia therapy.
  • Such agents include the immunoconjugate gemtuzumab ozogamicin, multidrug resistance inhibitors, farnesyl transferase inhibitors, histone deacetylase and proteosome inhibitors, antiangiogenesis agents, Fms-like tyrosine kinase 3 (FLT3) inhibitors, and apoptosis inhibitors.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Leukemia, Myeloid / drug therapy
  • [MeSH-minor] Acute Disease. Drug Delivery Systems / methods. Hematopoietic Stem Cell Transplantation. Humans. Remission Induction / methods


60. Yenson PR, Forrest D, Schmiegelow K, Dalal BI: Azathioprine-associated acute myeloid leukemia in a patient with Crohn's disease and thiopurine S-methyltransferase deficiency. Am J Hematol; 2008 Jan;83(1):80-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Azathioprine-associated acute myeloid leukemia in a patient with Crohn's disease and thiopurine S-methyltransferase deficiency.
  • We present such a patient who was a slow metabolizer for azathioprine, and developed a rapidly lethal form acute myeloid leukemia after relatively low dose exposure to the drug.
  • [MeSH-major] Azathioprine / adverse effects. Azathioprine / therapeutic use. Crohn Disease / drug therapy. Leukemia, Myeloid, Acute / pathology. Methyltransferases / deficiency. Methyltransferases / metabolism
  • [MeSH-minor] Adult. Bone Marrow / pathology. Female. Genotype. Humans


61. Tsapis M, Lieb M, Manzo F, Shankaranarayanan P, Herbrecht R, Lutz P, Gronemeyer H: HDAC inhibitors induce apoptosis in glucocorticoid-resistant acute lymphatic leukemia cells despite a switch from the extrinsic to the intrinsic death pathway. Int J Biochem Cell Biol; 2007;39(7-8):1500-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HDAC inhibitors induce apoptosis in glucocorticoid-resistant acute lymphatic leukemia cells despite a switch from the extrinsic to the intrinsic death pathway.
  • We have compared the growth inhibitory and apoptogenic potential of the pan-HDACi SAHA and the sub-class I selective HDAC inhibitor MS275, as well as valproic acid (VPA) on glucocorticoid sensitive and resistant B (B-ALL) and T (T-ALL) cell acute lymphoblastic leukemia cells and patients blasts.
  • In contrast, to our previous results with U937 acute myeloid leukemia (AML) cells which showed a similar activity of MS275 and SAHA in growth inhibition and apoptosis induction, both B and T-ALL cells were much more efficiently killed by SAHA and VPA than by MS275.
  • [MeSH-major] Apoptosis. Benzamides / pharmacology. Burkitt Lymphoma / pathology. Drug Resistance, Neoplasm. Glucocorticoids / pharmacology. Histone Deacetylase Inhibitors. Hydroxamic Acids / pharmacology. Leukemia-Lymphoma, Adult T-Cell / pathology. Pyridines / pharmacology

  • MedlinePlus Health Information. consumer health - Steroids.
  • Hazardous Substances Data Bank. Vorinostat .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. VALPROIC ACID .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17499001.001).
  • [ISSN] 1357-2725
  • [Journal-full-title] The international journal of biochemistry & cell biology
  • [ISO-abbreviation] Int. J. Biochem. Cell Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Benzamides; 0 / CDKN1A protein, human; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Glucocorticoids; 0 / Histone Deacetylase Inhibitors; 0 / Hydroxamic Acids; 0 / Pyridines; 0 / Receptors, TNF-Related Apoptosis-Inducing Ligand; 1ZNY4FKK9H / entinostat; 58IFB293JI / vorinostat; 614OI1Z5WI / Valproic Acid; 7S5I7G3JQL / Dexamethasone; EC 3.5.1.98 / Histone Deacetylases
  •  go-up   go-down


62. Sorà F, Antinori A, Piccirillo N, De Luca A, Chiusolo P, Cingolani A, Laurenti L, Rutella S, Ortona L, Leone G, Sica S: Highly active antiretroviral therapy and allogeneic CD34(+) peripheral blood progenitor cells transplantation in an HIV/HCV coinfected patient with acute myeloid leukemia. Exp Hematol; 2002 Mar;30(3):279-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Highly active antiretroviral therapy and allogeneic CD34(+) peripheral blood progenitor cells transplantation in an HIV/HCV coinfected patient with acute myeloid leukemia.
  • OBJECTIVE: To evaluate the safety, feasibility, and efficacy of allogeneic stem cell transplantation (SCT) for acute myelogenous leukemia (AML) in a young female coinfected by HIV and HCV undergoing highly active antiretroviral therapy (HAART).
  • RESULTS: The patient achieved prompt and durable engraftment with acute GVHD grade II easily managed with steroids; CMV prophylaxis was prolonged, no clinically relevant infectious complications developed early after transplantation and during follow-up.
  • HIV viremia was controlled by HAART although medication adherence was reduced early after transplantation and required drug adjustment.
  • [MeSH-major] Antiretroviral Therapy, Highly Active. HIV Infections / therapy. Hematopoietic Stem Cell Transplantation. Hepatitis C / therapy. Leukemia, Myeloid, Acute / therapy
  • [MeSH-minor] Adult. Antigens, CD34 / analysis. CD4 Lymphocyte Count. CD4-CD8 Ratio. Cyclosporine / therapeutic use. Female. Graft vs Host Disease / prevention & control. HIV / genetics. Hematopoietic Stem Cells / immunology. Humans. RNA, Viral / blood. Remission Induction. Transplantation, Homologous. Viremia / prevention & control


63. Kolitz JE, George SL, Marcucci G, Vij R, Powell BL, Allen SL, DeAngelo DJ, Shea TC, Stock W, Baer MR, Hars V, Maharry K, Hoke E, Vardiman JW, Bloomfield CD, Larson RA, Cancer and Leukemia Group B: P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808. Blood; 2010 Sep 02;116(9):1413-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808.
  • Cancer and Leukemia Group B 19808 (CALGB 19808) is the only randomized trial of a second-generation P-glycoprotein (Pgp) modulator in untreated patients with acute myeloid leukemia (AML) younger than age 60 years.
  • Inhibition of Pgp-mediated drug efflux by PSC-833 did not improve clinical outcomes in younger patients with untreated AML.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclosporins / therapeutic use. Leukemia, Myeloid, Acute / drug therapy. P-Glycoprotein / antagonists & inhibitors
  • [MeSH-minor] Adolescent. Adult. Cytarabine / administration & dosage. Daunorubicin / administration & dosage. Etoposide / administration & dosage. Female. Humans. Male. Middle Aged. Remission Induction. Survival Rate. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2005 May 1;105(9):3420-7 [15572587.001]
  • [Cites] Blood. 1999 Aug 1;94(3):1086-99 [10419902.001]
  • [Cites] Blood. 2006 Jun 15;107(12):4614-22 [16484584.001]
  • [Cites] Blood. 2007 May 15;109(10):4168-70 [17227830.001]
  • [Cites] Leuk Lymphoma. 2007 Aug;48(8):1587-99 [17701591.001]
  • [Cites] Exp Hematol. 2007 Dec;35(12):1793-800 [17923246.001]
  • [Cites] Leuk Res. 2008 Mar;32(3):465-73 [17826829.001]
  • [Cites] Leuk Res. 2009 Aug;33(8):1055-61 [19108889.001]
  • [Cites] Clin Cancer Res. 2009 May 15;15(10):3574-82 [19417029.001]
  • [Cites] Bone Marrow Transplant. 2009 Sep;44(6):353-9 [19289999.001]
  • [Cites] N Engl J Med. 2009 Sep 24;361(13):1235-48 [19776405.001]
  • [Cites] N Engl J Med. 2009 Sep 24;361(13):1249-59 [19776406.001]
  • [Cites] Blood. 2010 Jan 21;115(3):453-74 [19880497.001]
  • [Cites] Biol Blood Marrow Transplant. 2000;6(1):50-7 [10707999.001]
  • [Cites] Blood. 2000 May 1;95(9):2897-904 [10779437.001]
  • [Cites] J Clin Oncol. 2001 May 1;19(9):2482-92 [11331327.001]
  • [Cites] Leuk Lymphoma. 2001 Feb;40(5-6):613-23 [11426533.001]
  • [Cites] Blood. 2001 Dec 1;98(12):3212-20 [11719356.001]
  • [Cites] Blood. 2002 Aug 15;100(4):1224-32 [12149202.001]
  • [Cites] Clin Cancer Res. 2002 Sep;8(9):2812-9 [12231521.001]
  • [Cites] Blood. 2003 Aug 15;102(4):1202-10 [12663440.001]
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4642-9 [14673054.001]
  • [Cites] J Clin Oncol. 2004 Mar 15;22(6):1078-86 [15020609.001]
  • [Cites] Haematologica. 2004 Jul;89(7):782-90 [15257929.001]
  • [Cites] Blood. 2004 Oct 1;104(7):1940-51 [15217827.001]
  • [Cites] J Clin Oncol. 2004 Nov 1;22(21):4290-301 [15514371.001]
  • [Cites] J Clin Oncol. 1990 May;8(5):813-9 [2185339.001]
  • [Cites] J Natl Cancer Inst. 1995 Nov 1;87(21):1593-602 [7563202.001]
  • [Cites] Oncol Res. 1995;7(12):603-10 [8704277.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):1796-802 [9164187.001]
  • [Cites] Leukemia. 1998 Feb;12(2):192-9 [9519781.001]
  • [Cites] Blood. 1999 Feb 1;93(3):787-95 [9920827.001]
  • [Cites] Blood. 1999 Jun 15;93(12):4086-95 [10361105.001]
  • [Cites] Blood. 2005 Oct 15;106(8):2646-54 [15994288.001]
  • (PMID = 20522709.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00006363
  • [Grant] United States / NCI NIH HHS / CA / U10 CA032291; United States / NCI NIH HHS / CA / CA33601; United States / NCI NIH HHS / CA / U10 CA077658; United States / NCI NIH HHS / CA / CA02599; United States / NCI NIH HHS / CA / CA32291; United States / NCI NIH HHS / CA / CA41287; United States / NCI NIH HHS / CA / U10 CA035279; United States / NCI NIH HHS / CA / CA03927; United States / NCI NIH HHS / CA / U10 CA031946; United States / NCI NIH HHS / CA / U10 CA033601; United States / NCI NIH HHS / CA / CA35279; United States / NCI NIH HHS / CA / U10 CA077440; United States / NCI NIH HHS / CA / CA77440; United States / NCI NIH HHS / CA / U10 CA041287; United States / NCI NIH HHS / CA / U10 CA047559; United States / NCI NIH HHS / CA / CA47559; United States / NCI NIH HHS / CA / CA77658; United States / NCI NIH HHS / CA / CA31983; United States / NCI NIH HHS / CA / CA31946; United States / NCI NIH HHS / CA / U10 CA003927
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclosporins; 0 / P-Glycoprotein; 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; Q7ZP55KF3X / valspodar; ZS7284E0ZP / Daunorubicin
  • [Other-IDs] NLM/ PMC2938834
  •  go-up   go-down


64. López L, Gaztelurrutia L, Cuenca-Estrella M, Monzón A, Barrón J, Hernández JL, Pérez R: [Infection and colonization by Scedosporium prolificans]. Enferm Infecc Microbiol Clin; 2001 Aug-Sep;19(7):308-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Due to the resistance of this fungus to antifungal drugs, the therapeutic options are limited.
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Aged. Antifungal Agents / therapeutic use. Child, Preschool. Cystic Fibrosis / complications. Disease Susceptibility. Drug Resistance, Multiple, Fungal. Endocarditis / etiology. Female. Humans. Immunocompetence. Infant. Infant, Newborn. Leukemia, Myeloid / complications. Male. Middle Aged. Neutropenia / complications. Opportunistic Infections / epidemiology. Opportunistic Infections / microbiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Retrospective Studies. Spain / epidemiology. Wound Infection / microbiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11747789.001).
  • [ISSN] 0213-005X
  • [Journal-full-title] Enfermedades infecciosas y microbiología clínica
  • [ISO-abbreviation] Enferm. Infecc. Microbiol. Clin.
  • [Language] spa
  • [Publication-type] Case Reports; Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Antifungal Agents
  • [Number-of-references] 37
  •  go-up   go-down


65. Montesinos JJ, Sánchez-Valle E, Miranda-Peralta E, Gutiérrez-Romero M, Mayani H: Effect of rhGM-CSF on the kinetics of hematopoiesis in long-term marrow cultures from patients with acute myelogenous leukemia. Leuk Lymphoma; 2002 Dec;43(12):2383-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of rhGM-CSF on the kinetics of hematopoiesis in long-term marrow cultures from patients with acute myelogenous leukemia.
  • In the present study, we have assessed the effects of recombinant human Granulocyte-Macrophage Colony-Stimulating Factor (rhGM-CSF) in Dexter-type long-term marrow cultures (LTMC) from patients with acute myelogenous leukemia (AML).
  • Addition of rhGM-CSF to AML LTMC resulted in a significant increase in the number of total nucleated cells (1.3-4.3-fold, as compared to untreated cultures).
  • However, a simultaneous decrease in the numbers of myeloid progenitor cells (CFU) was observed.
  • Interestingly, there was a selective stimulation of the growth of leukemic progenitors (AML-CFU).
  • It is noteworthy that around 50% of the cells detected in the non-adherent fraction of rhGM-CSF-treated AML LTMC were blasts, whereas in untreated cultures, blasts corresponded to only 23% of the non-adherent cells, and the majority corresponded to cells of the monocyte-macrophage lineage.
  • These results indicate that rhGM-CSF is a cytokine with a significant stimulatory activity for the in vitro growth of AML progenitor andblast cells, and, together with previous reports in the literature, suggest that the use of rhGM-CSF in clinical settings must be taken with caution since this cytokine, although beneficial in reducing the risk of infections after chemotherapy, may induce the reappearance of the disease after treatment.
  • Further studies should be encouraged to understand in greater detail the effects of rhGM-CSF, and other cytokines, on the hematopoietic system of AML patients.
  • [MeSH-major] Granulocyte-Macrophage Colony-Stimulating Factor / pharmacology. Hematopoiesis / drug effects. Leukemia, Myeloid, Acute / pathology
  • [MeSH-minor] Adolescent. Adult. Bone Marrow Cells / pathology. Cell Culture Techniques / methods. Female. Humans. Kinetics. Male. Middle Aged. Neoplastic Stem Cells / drug effects. Neoplastic Stem Cells / pathology. Recombinant Proteins. Tumor Stem Cell Assay

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12613528.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Recombinant Proteins; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor
  •  go-up   go-down


66. Brooks TA, O'Loughlin KL, Minderman H, Bundy BN, Ford LA, Vredenburg MR, Bernacki RJ, Priebe W, Baer MR: The 4'-O-benzylated doxorubicin analog WP744 overcomes resistance mediated by P-glycoprotein, multidrug resistance protein and breast cancer resistance protein in cell lines and acute myeloid leukemia cells. Invest New Drugs; 2007 Apr;25(2):115-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The 4'-O-benzylated doxorubicin analog WP744 overcomes resistance mediated by P-glycoprotein, multidrug resistance protein and breast cancer resistance protein in cell lines and acute myeloid leukemia cells.
  • BACKGROUND: The synthetic 4'-O-benzylated doxorubicin analog WP744 was designed to abrogate transport by the multidrug resistance (MDR)-associated ATP-binding cassette (ABC) proteins P-glycoprotein (Pgp) and multidrug resistance protein (MRP-1).
  • We compared its uptake and cytotoxicity with those of doxorubicin and daunorubicin in cell lines overexpressing Pgp, MRP-1 or breast cancer resistance protein (BCRP) and in acute myeloid leukemia (AML) cells.
  • METHODS: Cellular uptake was studied by flow cytometry and cytotoxicity in 96-h 96-well cultures in cell lines overexpressing Pgp, MRP-1 or wild type (BCRP(R482)) or mutant (BCRP(R482T), BCRP(R482G)) BCRP and in pre-treatment AML marrow cells.
  • RESULTS: Uptake and cytotoxicity of WP744 were consistently greater than those of doxorubicin and daunorubicin at equimolar concentrations in all cell lines studied and in AML cells.
  • CONCLUSION: WP744 overcomes transport by Pgp, MRP-1 and BCRP in cell lines and AML cells and is a promising agent for clinical development in AML and other malignancies with broad-spectrum multidrug resistance.
  • [MeSH-major] ATP-Binding Cassette Transporters / physiology. ATP-Binding Cassette, Sub-Family B, Member 1 / physiology. Anthracyclines / pharmacology. Antineoplastic Agents / pharmacology. Drug Resistance, Neoplasm / drug effects. Leukemia, Myeloid / pathology. Neoplasm Proteins / physiology
  • [MeSH-minor] ATP Binding Cassette Transporter, Sub-Family G, Member 2. Adult. Aged. Antibiotics, Antineoplastic / metabolism. Cell Line, Tumor. Cell Survival / drug effects. Daunorubicin / metabolism. Doxorubicin / metabolism. Female. Fluorescence. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • Genetic Alliance. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2005 Mar 15;11(6):2320-6 [15788683.001]
  • [Cites] Br J Haematol. 2004 Nov;127(4):392-8 [15521915.001]
  • [Cites] Clin Cancer Res. 2004 Dec 1;10 (23 ):7896-902 [15585622.001]
  • [Cites] Clin Cancer Res. 2003 Aug 15;9(9):3320-8 [12960118.001]
  • [Cites] Br J Haematol. 2001 Nov;115(2):257-62 [11703319.001]
  • [Cites] Leukemia. 2004 Jul;18(7):1252-7 [15208643.001]
  • [Cites] Mol Cancer Ther. 2003 Nov;2(11):1195-205 [14617793.001]
  • [Cites] NeuroRx. 2005 Jan;2(1):86-98 [15717060.001]
  • [Cites] Cancer Res. 2001 Sep 15;61(18):6635-9 [11559526.001]
  • [Cites] J Surg Res. 2004 Oct;121(2):187-96 [15501458.001]
  • [Cites] J Surg Res. 2004 Dec;122(2):231-9 [15555623.001]
  • [Cites] Leukemia. 2002 Aug;16(8):1443-7 [12145683.001]
  • [Cites] Clin Cancer Res. 2003 Nov 1;9(14 ):5171-7 [14613996.001]
  • [Cites] Biochem Pharmacol. 2004 Jan 15;67(2):353-64 [14698047.001]
  • [Cites] Cytometry. 2002 Jun 1;48(2):59-65 [12116365.001]
  • [Cites] Anticancer Res. 2001 Nov-Dec;21(6A):3777-84 [11911247.001]
  • [Cites] Nat Rev Cancer. 2002 Jan;2(1):48-58 [11902585.001]
  • (PMID = 17072745.001).
  • [ISSN] 0167-6997
  • [Journal-full-title] Investigational new drugs
  • [ISO-abbreviation] Invest New Drugs
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA16056; United States / NCI NIH HHS / CA / R01 CA 73872; United States / NCI NIH HHS / CA / R21 CA 98457; United States / NCI NIH HHS / CA / T32 CA 09072-28
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ABCG2 protein, human; 0 / ATP Binding Cassette Transporter, Sub-Family G, Member 2; 0 / ATP-Binding Cassette Transporters; 0 / ATP-Binding Cassette, Sub-Family B, Member 1; 0 / Anthracyclines; 0 / Antibiotics, Antineoplastic; 0 / Antineoplastic Agents; 0 / Neoplasm Proteins; 0 / WP 744; 80168379AG / Doxorubicin; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


67. Leinoe EB, Hoffmann MH, Kjaersgaard E, Johnsen HE: Multiple platelet defects identified by flow cytometry at diagnosis in acute myeloid leukaemia. Br J Haematol; 2004 Oct;127(1):76-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple platelet defects identified by flow cytometry at diagnosis in acute myeloid leukaemia.
  • Summary Previous findings of megakaryocytic hypogranulation and dysmegakaryocytopoietic features in acute myeloid leukaemia (AML) strongly indicate defects in platelet production.
  • The present study examined platelet function at diagnosis in 50 AML patients by whole blood flow cytometry.
  • The presented data indicate that AML pathogenesis may result in multiple platelet defects, involving adhesion, aggregation, and secretion and demonstrate that flow cytometry is a feasible method for platelet function analysis in patients with thrombocytopenia.
  • [MeSH-major] Blood Platelets / physiology. Leukemia, Myeloid / blood
  • [MeSH-minor] Acute Disease. Adenosine Diphosphate / pharmacology. Adult. Aged. Aged, 80 and over. Female. Flow Cytometry / methods. Humans. Male. Middle Aged. P-Selectin / blood. Platelet Activation / drug effects. Platelet Aggregation / drug effects. Platelet Function Tests / methods. Receptors, Thrombin / physiology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 Blackwell Publishing Ltd
  • (PMID = 15384980.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / P-Selectin; 0 / Receptors, Thrombin; 61D2G4IYVH / Adenosine Diphosphate
  •  go-up   go-down


68. Wu XX, Da WM, Li HH, Zhao Y, Wang QS, Wang SH, Zhu HY: [Effects of FLAG regimen in treatment of refractory or relapsed acute myeloid leukemia]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Jun;13(3):394-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effects of FLAG regimen in treatment of refractory or relapsed acute myeloid leukemia].
  • In order to evaluate the effects of FLAG regimen in treatment of refractory and relapsed acute myeloid leukemia (AML), 27 patients with refractory or relapsed acute myeloid leukemia (10 refractory AML patients, 17 relapsed AML patients) were treated with FLAG regimen.

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15972128.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 143011-72-7 / Granulocyte Colony-Stimulating Factor; FA2DM6879K / Vidarabine
  •  go-up   go-down


69. Portugal RD, Garnica M, Nucci M: Index to predict invasive mold infection in high-risk neutropenic patients based on the area over the neutrophil curve. J Clin Oncol; 2009 Aug 10;27(23):3849-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We tested the D-index in 11 patients with acute myeloid leukemia (AML) who developed IMI during neutropenia and 33 AML patients without IMI (controls).
  • [MeSH-major] Antifungal Agents / therapeutic use. Antineoplastic Agents / adverse effects. Mycoses / etiology. Mycoses / prevention & control. Neutropenia / chemically induced. Neutropenia / complications. Neutrophils
  • [MeSH-minor] Adolescent. Adult. Area Under Curve. Female. Humans. Leukemia, Myeloid, Acute / drug therapy. Leukocyte Count. Male. Mathematical Computing. Middle Aged. Patient Selection. Predictive Value of Tests. ROC Curve. Risk Assessment / methods. Risk Factors. Severity of Illness Index

  • MedlinePlus Health Information. consumer health - Fungal Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19597026.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antifungal Agents; 0 / Antineoplastic Agents
  •  go-up   go-down


70. Lane JE, Brown CA, Lesher JL Jr, Hashem B, Marzec T: Pressure-induced bullae and sweat gland necrosis following chemotherapy induction. Am J Med; 2004 Sep 15;117(6):441-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Blister / chemically induced. Drug-Related Side Effects and Adverse Reactions. Sweat Gland Diseases / chemically induced. Sweat Glands / drug effects. Sweat Glands / pathology
  • [MeSH-minor] Acute Disease. Adult. Antibiotics, Antineoplastic / adverse effects. Antimetabolites, Antineoplastic / adverse effects. Cytarabine / adverse effects. Drug Eruptions / etiology. Humans. Idarubicin / adverse effects. Leukemia, Myeloid / therapy. Male. Necrosis. Remission Induction

  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15380504.001).
  • [ISSN] 0002-9343
  • [Journal-full-title] The American journal of medicine
  • [ISO-abbreviation] Am. J. Med.
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antimetabolites, Antineoplastic; 04079A1RDZ / Cytarabine; ZRP63D75JW / Idarubicin
  •  go-up   go-down


71. Ustün C, Beksac M, Dalva K, Koc H, Konuk N, Ilhan O, Ozcan M, Topcuoglu P, Sertkaya D, Hayran M: In vivo use of all-trans retinoic acid prior to induction chemotherapy improves complete remission rate and increases rhodamine 123 uptake in patients with de novo acute myeloid leukemia. Med Oncol; 2002;19(1):59-67
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vivo use of all-trans retinoic acid prior to induction chemotherapy improves complete remission rate and increases rhodamine 123 uptake in patients with de novo acute myeloid leukemia.
  • All-trans retinoic acid (ATRA) is used in the treatment of acute promyelocytic leukemia.
  • Because ATRA has effects (increase in apoptosis, suppression of bcl-2), it has also been used for the treatment of other French-American-British (FAB) subtypes of acute myelogenous leukemia (AML).
  • To find out the in vivo and in vitro effects of ATRA in AML, we analyzed 37 patients with de novo AML.
  • In conclusion, ATRA treatment prior to RI treatment may improve the CR rate in patients with de novo AML, which seems to be related to its beneficial effect on multidrug resistance.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Cytarabine / therapeutic use. Leukemia, Myeloid / drug therapy. Rhodamine 123 / metabolism. Tretinoin / therapeutic use
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Aged. Antigens, CD / metabolism. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Biomarkers, Tumor / metabolism. Case-Control Studies. Drug Resistance, Multiple. Etoposide / administration & dosage. Female. Fluorescent Dyes / metabolism. Humans. Idarubicin / administration & dosage. Immunophenotyping. Leukocyte Count. Male. Middle Aged. Proto-Oncogene Proteins c-bcl-2 / metabolism. Remission Induction. Treatment Outcome

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1995 Sep 15;86(6):2329-42 [7545025.001]
  • [Cites] Leukemia. 1995 Jul;9(7):1121-5 [7630182.001]
  • [Cites] Br J Haematol. 1999 Apr;105(1):215-24 [10233386.001]
  • [Cites] Leukemia. 1997 Nov;11(11):1850-7 [9369417.001]
  • [Cites] Blood. 1999 Apr 15;93(8):2478-84 [10194425.001]
  • [Cites] Leukemia. 1992 Sep;6(9):879-85 [1355575.001]
  • [Cites] Int J Oncol. 1994 Mar;4(3):649-54 [21566972.001]
  • [Cites] Blood. 1993 Jan 1;81(1):151-7 [8417786.001]
  • [Cites] Br J Haematol. 2000 Jan;108(1):40-7 [10651722.001]
  • [Cites] Blood. 1992 Jan 15;79(2):473-6 [1370388.001]
  • [Cites] J Natl Cancer Inst. 1989 Jan 18;81(2):116-24 [2562856.001]
  • [Cites] Leukemia. 1993 Jun;7(6):825-31 [8099135.001]
  • [Cites] Blood. 1994 Jul 15;84(2):595-600 [8025285.001]
  • [Cites] Leukemia. 1994 Dec;8(12):2065-75 [7807996.001]
  • [Cites] Eur J Haematol. 1999 Mar;62(3):143-8 [10089890.001]
  • [Cites] Eur J Cancer. 1996 Jun;32A(6):921-6 [8763333.001]
  • [Cites] Cancer Res. 1992 Oct 1;52(19):5407-11 [1394146.001]
  • [Cites] Blood. 1997 Dec 15;90(12):4710-8 [9389686.001]
  • [Cites] J Natl Cancer Inst. 1991 May 15;83(10):708-12 [2023272.001]
  • [Cites] Blood. 1998 Sep 1;92 (5):1768-75 [9716607.001]
  • [Cites] Leuk Lymphoma. 1997 Sep;27(1-2):119-25 [9373203.001]
  • [Cites] Clin Cancer Res. 1998 May;4(5):1345-55 [9607596.001]
  • [Cites] Leuk Lymphoma. 1998 Jan;28(3-4):315-27 [9517503.001]
  • [Cites] Med Oncol Tumor Pharmacother. 1992;9(2):101-5 [1364132.001]
  • [Cites] Br J Haematol. 1994 Sep;88(1):105-9 [7803231.001]
  • [Cites] Leukemia. 1996 Mar;10(3):410-6 [8642855.001]
  • [Cites] Br J Haematol. 1991 Jan;77(1):50-3 [1671821.001]
  • [Cites] Leukemia. 1995 May;9(5):789-98 [7769841.001]
  • [Cites] Ann Oncol. 1998 Feb;9(2):159-65 [9553660.001]
  • [Cites] Br J Haematol. 2000 Jan;108(1):90-2 [10651729.001]
  • [Cites] Br J Haematol. 1995 Oct;91(2):374-9 [8547078.001]
  • [Cites] Leuk Res. 1990;14(1):11-21 [2304354.001]
  • [Cites] Med Oncol. 1998 Sep;15(3):183-90 [9819795.001]
  • [Cites] Cancer Res. 1996 Mar 15;56(6):1253-5 [8640809.001]
  • [Cites] Leukemia. 1999 Nov;13(11):1881-92 [10557066.001]
  • [Cites] Bull Cancer. 1994 Oct;81(10):894-6 [7734774.001]
  • [Cites] Leukemia. 2000 Apr;14 (4):620-8 [10764147.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 May 9;92(10):4507-11 [7753834.001]
  • [Cites] Blood. 1996 Aug 15;88(4):1390-8 [8695858.001]
  • [Cites] Blood. 1993 Jun 1;81(11):3091-6 [7684624.001]
  • [Cites] Eur J Cancer. 1996 Jun;32A(6):1034-8 [8763345.001]
  • [Cites] Br J Cancer. 1998 Jun;77(12):2129-37 [9649124.001]
  • [Cites] Leukemia. 1995 Oct;9(10):1667-73 [7564507.001]
  • [Cites] Leukemia. 1993 Jul;7(7):1012-9 [7686602.001]
  • [Cites] J Histochem Cytochem. 1977 Jul;25(7):935-41 [894009.001]
  • [Cites] Ann Hematol. 1997 Sep;75(3):81-6 [9368475.001]
  • [Cites] Eur J Cancer. 1996 Jun;32A(6):1062-9 [8763348.001]
  • (PMID = 12025892.001).
  • [ISSN] 1357-0560
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antimetabolites, Antineoplastic; 0 / Biomarkers, Tumor; 0 / Fluorescent Dyes; 0 / Proto-Oncogene Proteins c-bcl-2; 04079A1RDZ / Cytarabine; 1N3CZ14C5O / Rhodamine 123; 5688UTC01R / Tretinoin; 6PLQ3CP4P3 / Etoposide; ZRP63D75JW / Idarubicin; GIMEMA ALL 0394
  •  go-up   go-down


72. Faderl S, Estrov Z, Kantarjian HM, Harris D, Van Q, Fokt I, Przewloka T, Godlewski C, Woynarowski JM, Priebe W: WP744, a novel anthracycline with enhanced proapoptotic and antileukemic activity. Anticancer Res; 2001 Nov-Dec;21(6A):3777-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: MDR1 or MRP1 drug resistance mechanisms seriously limit the efficacy of anthracyclines such as doxorubicin, in the treatment of acute myeloid leukemia (AML).
  • Our studies indicated that reducing basicity, increasing steric hindrance at C-4', and/or lipophilicity may help circumvent P-glycoprotein (P-gp)-mediated anthracycline efflux and thus increase drug retention in MDR-positive cells.
  • METHODS AND RESULTS: In three AML cell lines (K562, KBM-3, and OCIM2) WP744 was markedly more potent (IC50 values of 0.18, <0.05, and <0.05 microg/ml, respectively) than doxorubicin (IC50 values of >0.5, 0.07, and 0.09 microg/ml, respectively).
  • Likewise, WP744 inhibited the colony formation by AML-CFU cells from fresh bone marrow of three AML patients more strongly than doxorubicin.
  • Accordingly, caspase 3 activity was elevated in the lysates from drug-treated cells.
  • Finally, WP744 at 0.05 microM and greater was a potent inducer of apoptosis (by quantitative DNA fragmentation) in cultured human acute lymphoblastic leukemia (ALL) CEM cells, compared to 0.5 microM doxorubicin needed for a similar effect.
  • CONCLUSION: The novel anthracycline WP744 was found to be an antileukemic agent with proapoptotic activity superior to that of doxorubicin.
  • [MeSH-major] Anthracyclines. Antibiotics, Antineoplastic / pharmacokinetics. Antibiotics, Antineoplastic / pharmacology. Apoptosis / drug effects. Doxorubicin / analogs & derivatives. Leukemia, Monocytic, Acute / drug therapy. Leukemia, Myeloid, Acute / drug therapy
  • [MeSH-minor] Adult. Aged. Caspase 3. Caspases / metabolism. Cell Division / drug effects. DNA Fragmentation. Female. Growth Inhibitors / pharmacology. Humans. K562 Cells / drug effects. K562 Cells / pathology. Male. Middle Aged. Poly(ADP-ribose) Polymerases / metabolism. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11911247.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA50270; United States / NCI NIH HHS / CA / CA55320; United States / NCI NIH HHS / CA / CA78706
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Anthracyclines; 0 / Antibiotics, Antineoplastic; 0 / Growth Inhibitors; 0 / WP 744; 80168379AG / Doxorubicin; EC 2.4.2.30 / Poly(ADP-ribose) Polymerases; EC 3.4.22.- / CASP3 protein, human; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspases
  •  go-up   go-down


73. Sonneck K, Florian S, Böhm A, Krauth MT, Kondo R, Hauswirth AW, Gleixner KV, Aichberger KJ, Derdak S, Pickl WF, Sperr WR, Schwartz LB, Valent P: Evaluation of biologic activity of tryptase secreted from blast cells in acute myeloid leukemia. Leuk Lymphoma; 2006 May;47(5):897-906
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of biologic activity of tryptase secreted from blast cells in acute myeloid leukemia.
  • A number of autocrine and paracrine growth regulators are considered to be involved in the survival and proliferation of blast cells in acute myeloid leukemia (AML).
  • We have recently shown that blast cells in a group of patients with AML produce and secrete the mitogenic enzyme tryptase.
  • In the present study, we examined functional effects of tryptase in the context of AML.
  • As assessed by 3H-thymidine uptake experiments, tryptase-containing serum from patients with AML as well as heparin-complexed recombinant tryptase were found to promote the proliferation of cultured bone marrow- and lung fibroblasts in a dose-dependent manner.
  • Tryptase also induced the expression of mRNA for GM-CSF and SCF, two cytokines known to promote growth of AML cells, in cultured bone marrow fibroblasts.
  • Neither recombinant tryptase nor tryptase-rich serum of AML patients, showed an effect on the growth of leukemic blast cells irrespective of the FAB category or expression of protease-activated receptor (PAR)-2, a putative molecular target of tryptase.
  • Together, tryptase is secreted from AML blasts as a biologically active molecule that may exhibit paracrine rather than autocrine effects in AML.
  • [MeSH-major] Blast Crisis / enzymology. Leukemia, Myeloid / enzymology. Serine Endopeptidases / pharmacology
  • [MeSH-minor] Acute Disease. Adult. Aged. Bone Marrow Cells / cytology. Cell Proliferation / drug effects. Cells, Cultured. Cytokines / genetics. Female. Fibroblasts / cytology. Gene Expression Regulation / drug effects. Humans. Male. Middle Aged. Paracrine Communication. Tritium / pharmacokinetics. Tryptases

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • Hazardous Substances Data Bank. TRITIUM, RADIOACTIVE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leuk Lymphoma. 2006 May;47(5):789-90 [16753862.001]
  • (PMID = 16753876.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / AI20487
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cytokines; 10028-17-8 / Tritium; EC 3.4.21.- / Serine Endopeptidases; EC 3.4.21.59 / Tryptases
  •  go-up   go-down


74. Faderl S, Ferrajoli A, Wierda W, Huang X, Verstovsek S, Ravandi F, Estrov Z, Borthakur G, Kwari M, Kantarjian HM: Clofarabine combinations as acute myeloid leukemia salvage therapy. Cancer; 2008 Oct 15;113(8):2090-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clofarabine combinations as acute myeloid leukemia salvage therapy.
  • BACKGROUND: Outcome of patients with relapsed acute myeloid leukemia (AML) remains unsatisfactory.
  • Clofarabine is a nucleoside analog with activity in adult AML.
  • Combinations with cytarabine in AML are feasible and effective.
  • Idarubicin is another active AML drug, which has not yet been tested with clofarabine.
  • Patients with primary refractory or first-relapse AML were assigned to either clofarabine plus idarubicin (CI) if previously exposed to cytarabine with a response lasting <12 months, or clofarabine and idarubicin plus cytarabine (CIA) for responses > or = 12 months, or if never exposed to cytarabine.
  • [MeSH-major] Adenine Nucleotides / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Arabinonucleosides / administration & dosage. Cytarabine / administration & dosage. Idarubicin / administration & dosage. Leukemia, Myeloid, Acute / drug therapy. Salvage Therapy / methods
  • [MeSH-minor] Adult. Aged. Humans. Maximum Tolerated Dose. Middle Aged

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 American Cancer Society.
  • [CommentIn] Cancer. 2008 Oct 15;113(8):1995-8 [18780321.001]
  • (PMID = 18756533.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adenine Nucleotides; 0 / Arabinonucleosides; 04079A1RDZ / Cytarabine; 762RDY0Y2H / clofarabine; ZRP63D75JW / Idarubicin
  • [Other-IDs] NLM/ NIHMS593643; NLM/ PMC4163782
  •  go-up   go-down


75. Yamaguchi Y, Usui N, Dobashi N, Yano S, Yahagi Y, Takei Y, Sugiyama K, Ogasawara Y, Saito T, Minami J, Kobayashi T, Katsube A, Kamiyama Y, Machishima T, Morikawa N, Otsubo H, Kaito K, Asai O, Aiba K: Gemtuzumab ozogamicin (GO) in relapsed/refractory patients with acute myeloid leukemia. Gan To Kagaku Ryoho; 2009 Jul;36(7):1105-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gemtuzumab ozogamicin (GO) in relapsed/refractory patients with acute myeloid leukemia.
  • We conducted to evaluate the efficacy and toxicity of GO in our patients with relapsed or refractory AML retrospectively.
  • PATIENTS AND METHODS: Data were collected between March 1, 2000, and March 1, 2006, on 10 patients with relapsed or refractory AML(excluding FAB: M3).
  • CONCLUSION: GO is a valuable new treatment option for relapsed or refractory AML patients, however, the benefit from single agent appears insufficient.
  • On going clinical trials including combination with other antileukemic agents might better define the role of GO.
  • [MeSH-major] Aminoglycosides / therapeutic use. Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Leukemia, Myeloid, Acute / drug therapy
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal, Humanized. Drug-Induced Liver Injury. Female. Humans. Hypersensitivity / etiology. Male. Middle Aged. Recurrence. Remission Induction. Retrospective Studies. Thrombocytopenia / chemically induced

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19620797.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Aminoglycosides; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / gemtuzumab
  •  go-up   go-down


76. Ak I, Aslan V, Vardareli E, Gülbaş Z: Assessment of the P-glycoprotein expression by 99mTc-MIBI bone marrow imaging in patients with untreated leukaemia. Nucl Med Commun; 2003 Apr;24(4):397-402
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The ability of cancer cells to become simultaneously resistant to different drugs is a significant impediment to successful chemotherapy.
  • 99mTc-MIBI has been reported to be a transport substrate for P-glycoprotein (Pgp).
  • [MeSH-major] Bone Marrow / metabolism. Bone Marrow / radionuclide imaging. Leukemia / metabolism. Leukemia / radionuclide imaging. P-Glycoprotein / metabolism. Technetium Tc 99m Sestamibi / pharmacokinetics
  • [MeSH-minor] Adult. Aged. Drug Resistance, Multiple. Female. Humans. Leukemia, Myeloid, Acute / metabolism. Leukemia, Myeloid, Acute / radionuclide imaging. Male. Middle Aged. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / radionuclide imaging. Radiopharmaceuticals / pharmacokinetics. Reproducibility of Results. Sensitivity and Specificity. Statistics as Topic. Tissue Distribution. Whole-Body Counting / methods

  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12673168.001).
  • [ISSN] 0143-3636
  • [Journal-full-title] Nuclear medicine communications
  • [ISO-abbreviation] Nucl Med Commun
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Validation Studies
  • [Publication-country] England
  • [Chemical-registry-number] 0 / P-Glycoprotein; 0 / Radiopharmaceuticals; 971Z4W1S09 / Technetium Tc 99m Sestamibi
  •  go-up   go-down


77. O'Farrell AM, Yuen HA, Smolich B, Hannah AL, Louie SG, Hong W, Stopeck AT, Silverman LR, Lancet JE, Karp JE, Albitar M, Cherrington JM, Giles FJ: Effects of SU5416, a small molecule tyrosine kinase receptor inhibitor, on FLT3 expression and phosphorylation in patients with refractory acute myeloid leukemia. Leuk Res; 2004 Jul;28(7):679-89
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of SU5416, a small molecule tyrosine kinase receptor inhibitor, on FLT3 expression and phosphorylation in patients with refractory acute myeloid leukemia.
  • Acute myeloid leukemia (AML) is associated with dysregulated hematopoietic cell proliferation and increased bone marrow angiogenesis, each regulated by signaling through receptor tyrosine kinases (RTKs).
  • SU5416 is a small molecule inhibitor of VEGF receptors, c-kit and FLT3 and therefore provides a novel opportunity to target both angiogenesis and proliferation in AML.
  • Since AML provides a unique platform to evaluate mechanism of action of small molecule inhibitors, investigation of the effect of SU5416 on FLT3 expression and phosphorylation in blood and bone marrow was an additional focus of this trial.
  • Although no clear correlation with clinical response was observed, analysis of patient plasma drug levels suggested that a threshold SU5416 concentration of 15 microM was associated with FLT3 inhibition.
  • This observation was supported by data from an ex vivo model where AML cells were spiked into human blood, established to mimic the clinical setting and enable more rigorous analysis of effect of SU5416.
  • [MeSH-major] Indoles / pharmacology. Leukemia, Myeloid / drug therapy. Proto-Oncogene Proteins / drug effects. Pyrroles / pharmacology. Receptor Protein-Tyrosine Kinases / drug effects
  • [MeSH-minor] Acute Disease. Adult. Aged. Bone Marrow / chemistry. Down-Regulation / drug effects. Female. Humans. Male. Membrane Proteins / blood. Middle Aged. Mutation. Phosphorylation / drug effects. Protein-Tyrosine Kinases / antagonists & inhibitors. Stem Cell Factor / blood. fms-Like Tyrosine Kinase 3

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15158089.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Indoles; 0 / Membrane Proteins; 0 / Proto-Oncogene Proteins; 0 / Pyrroles; 0 / Stem Cell Factor; 0 / flt3 ligand protein; 71IA9S35AJ / Semaxinib; EC 2.7.10.1 / FLT3 protein, human; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3
  •  go-up   go-down


78. Buckwalter M, Dowell JA, Korth-Bradley J, Gorovits B, Mayer PR: Pharmacokinetics of gemtuzumab ozogamicin as a single-agent treatment of pediatric patients with refractory or relapsed acute myeloid leukemia. J Clin Pharmacol; 2004 Aug;44(8):873-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pharmacokinetics of gemtuzumab ozogamicin as a single-agent treatment of pediatric patients with refractory or relapsed acute myeloid leukemia.
  • Gemtuzumab ozogamicin is currently approved to treat CD33-positive acute myeloid leukemia (AML) in first relapse in patients older than age 60 years.
  • The objective of this study was to characterize the pharmacokinetics of gemtuzumab ozogamicin in pediatric patients with relapsed or refractory AML.
  • The study population comprised 29 subjects younger than age 18 with AML in first relapse.
  • Increases in AUC and decreases in both CL and V(ss) from the first dose to the second dose were consistent with those of the adult population.
  • Mean pharmacokinetic values are similar to values reported in adults.
  • Individual children demonstrated large intersubject variability, similar to adults.
  • The pharmacokinetics of gemtuzumab ozogamicin in pediatric patients closely follow the profile and variability of adult patients.
  • [MeSH-major] Aminoglycosides / pharmacokinetics. Antibodies, Monoclonal / pharmacokinetics. Antineoplastic Agents / pharmacokinetics. Leukemia, Myeloid / drug therapy
  • [MeSH-minor] Acute Disease. Adolescent. Antibodies, Monoclonal, Humanized. Antigens, CD / analysis. Antigens, Differentiation, Myelomonocytic / analysis. Area Under Curve. Child. Child, Preschool. Female. Half-Life. Humans. Infant. Infusions, Intravenous. Male. Metabolic Clearance Rate. Recurrence. Sialic Acid Binding Ig-like Lectin 3

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • SciCrunch. DrugBank: Data: Chemical .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15286091.001).
  • [ISSN] 0091-2700
  • [Journal-full-title] Journal of clinical pharmacology
  • [ISO-abbreviation] J Clin Pharmacol
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoglycosides; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / Antineoplastic Agents; 0 / CD33 protein, human; 0 / Sialic Acid Binding Ig-like Lectin 3; 0 / gemtuzumab
  •  go-up   go-down


79. Lemez P, Urbánek V: Chemotherapy for acute myeloid leukemias with cytosine arabinoside, daunorubicin, etoposide, and mitoxantrone may cause permanent oligoasthenozoospermia or amenorrhea in middle-aged patients. Neoplasma; 2005;52(5):398-401
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy for acute myeloid leukemias with cytosine arabinoside, daunorubicin, etoposide, and mitoxantrone may cause permanent oligoasthenozoospermia or amenorrhea in middle-aged patients.
  • The aim was to follow-up gonadal functions in long-term survivors of acute myeloid leukemias (AML) after intensive chemotherapy based on high-doses of cytosine arabinoside (Ara-C) and anthracyclines in the study UHKT-911.
  • Adult patients were treated with at least 3 cycles of chemotherapy including 1-3 courses of Ara-C 10 x 2000 mg/m2/12 h and daunorubicin (DNR) 2 x 45 mg/m2/d.
  • Intensive chemotherapy with high-doses of Ara-C and DNR plus one cycle of etoposide and mitoxantrone may cause permanent gonadal dysfunction in middle-aged patients with AML.
  • [MeSH-major] Amenorrhea / chemically induced. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Leukemia, Myeloid / drug therapy. Spermatozoa / drug effects
  • [MeSH-minor] Acute Disease. Adult. Bone Marrow Transplantation. Cytarabine / administration & dosage. Cytarabine / adverse effects. Daunorubicin / administration & dosage. Daunorubicin / adverse effects. Etoposide / administration & dosage. Etoposide / adverse effects. Female. Humans. Male. Middle Aged. Mitoxantrone / administration & dosage. Mitoxantrone / adverse effects. Oligospermia / chemically induced. Sperm Motility / drug effects

  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16151584.001).
  • [ISSN] 0028-2685
  • [Journal-full-title] Neoplasma
  • [ISO-abbreviation] Neoplasma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Slovakia
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; BZ114NVM5P / Mitoxantrone; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


80. Sun XF, Han B, Feng J, Zhou DB, Wang SJ, Xu Y, Chen JL, Jiao L, Zhang W, Li J, Duan MH, Zhu TN, Zou N, Hua BL, Cai HC, Zhao YQ: [Clinical features of invasive pulmonary fungal infection secondary to malignant blood diseases]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2009 Oct;31(5):575-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: The incidences of IPFI secondary to acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), non-Hodgkin's lymphoma (NHL), and aplastic anemia (AA) were 4.6%, 3.2%, 2.8%, and 2.5%, respectively.
  • In patients with IPFI secondary to AML, 88.5% (23/26) of the patients suffered from the infections during the non-remission (NR) period (including relapse), and 11.5% (3/26) in the complete-remission (CR) period.
  • More than half of patients with fluconazole or itraconazole as the first-line therapy had to switch to other medicines because of poor infection control.
  • CONCLUSIONS: IPFI secondary to MBD is most common in AML patients.
  • Patients with NR of AML, neutropenia or agranulocytosis, and long-term broad-spectrum antibiotics usage are susceptible to IPFI.
  • Fluconazole and itraconazole have low efficacy, and other more potent anti-fungal medicines should be considered.
  • [MeSH-major] Hematologic Neoplasms / complications. Lung Diseases, Fungal / diagnosis. Lung Diseases, Fungal / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Retrospective Studies. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19968074.001).
  • [ISSN] 1000-503X
  • [Journal-full-title] Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae
  • [ISO-abbreviation] Zhongguo Yi Xue Ke Xue Yuan Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


81. Ganser A, Heil G, Seipelt G, Hofmann W, Fischer JT, Langer W, Brockhaus W, Kolbe K, Ittel TH, Brack N, Fuhr HG, Knuth P, Höffken K, Bergmann L, Hoelzer D: Intensive chemotherapy with idarubicin, ara-C, etoposide, and m-AMSA followed by immunotherapy with interleukin-2 for myelodysplastic syndromes and high-risk Acute Myeloid Leukemia (AML). Ann Hematol; 2000 Jan;79(1):30-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intensive chemotherapy with idarubicin, ara-C, etoposide, and m-AMSA followed by immunotherapy with interleukin-2 for myelodysplastic syndromes and high-risk Acute Myeloid Leukemia (AML).
  • Intensive chemotherapy followed by treatment with interleukin-2 (IL-2) was evaluated in a prospective, randomized, multicenter trial including 18 patients with refractory anemia with excess of blasts in transformation (RAEB-T), 86 patients with acute myeloid leukemia (AML) evolving from myelodysplastic syndromes, and six patients with secondary AML after previous chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Immunotherapy. Interleukin-2 / therapeutic use. Leukemia, Myeloid / drug therapy. Myelodysplastic Syndromes / drug therapy. Myelodysplastic Syndromes / therapy
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Aged. Cytarabine / administration & dosage. Dose-Response Relationship, Drug. Etoposide / administration & dosage. Female. Humans. Idarubicin / administration & dosage. Male. Middle Aged. Prospective Studies. Survival Rate


82. Kwon JH, Kim I, Lee YG, Koh Y, Park HC, Song EY, Kim HK, Yoon SS, Lee DS, Park SS, Shin HY, Park S, Park MH, Ahn HS, Kim BK: Clinical course of non-severe aplastic anemia in adults. Int J Hematol; 2010 Jun;91(5):770-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical course of non-severe aplastic anemia in adults.
  • The clinical course of non-severe aplastic anemia is variable, and risk factors related to disease progression are not well known.
  • We reviewed clinical and laboratory data of the patients who were diagnosed with non-severe aplastic anemia from 1997 to 2007 at Seoul National University Hospital and analyzed the clinical course and outcomes in these patients.
  • We defined non-severe aplastic anemia as hypocellular marrow with cytopenia in the peripheral blood, which does not meet the criteria for severe aplastic anemia (at least two of the following: ANC < 500/microl, platelet < 20,000/microl or reticulocyte < 20,000/microl).
  • Sixty-two patients who were treated with oxymetholone, ATG/ALG, cyclosporin or other agents after initial diagnosis showed significantly lower levels of initial hemoglobin, red blood cell count and platelet count than those who did not receive any treatment.
  • Sixteen patients showed overall improvement, whereas three patients developed secondary hematologic disease, acute myeloid leukemia, myelodysplastic syndrome and paroxysmal nocturnal hemoglobinuria.
  • Non-severe aplastic anemia has a relatively indolent and mild clinical course.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Androgens / therapeutic use. Cyclosporine / therapeutic use. Female. Humans. Immunosuppressive Agents / therapeutic use. Korea / epidemiology. Male. Middle Aged. Oxymetholone / therapeutic use. Prognosis. Risk Factors. Survival Analysis. Young Adult

  • Genetic Alliance. consumer health - Anemia.
  • Genetic Alliance. consumer health - Aplastic Anemia.
  • MedlinePlus Health Information. consumer health - Aplastic Anemia.
  • Hazardous Substances Data Bank. OXYMETHOLONE .
  • Hazardous Substances Data Bank. CYCLOSPORIN A .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1983 Jan 20;308(3):113-8 [6336819.001]
  • [Cites] Blood. 1997 Jul 15;90(2):858-64 [9226187.001]
  • [Cites] Br J Haematol. 2008 Dec;143(5):738-43 [19062343.001]
  • [Cites] Int J Hematol. 2009 May;89(4):409-13 [19343478.001]
  • [Cites] Br J Haematol. 2003 Dec;123(5):782-801 [14632769.001]
  • [Cites] Blood. 2000 Mar 15;95(6):1931-4 [10706857.001]
  • [Cites] Blood. 2003 Nov 15;102(10):3584-6 [12881307.001]
  • [Cites] Blood. 1976 Jul;48(1):63-70 [779871.001]
  • [Cites] Blood. 2004 Apr 1;103(7):2490-7 [14656884.001]
  • [Cites] Blood. 1995 Jan 1;85(1):283-90 [7803802.001]
  • [Cites] Int J Hematol. 2000 Jul;72(1):118-23 [10979223.001]
  • [Cites] Leuk Res. 2010 Oct;34(10):1344-50 [20427085.001]
  • [Cites] JAMA. 2003 Mar 5;289(9):1130-5 [12622583.001]
  • [Cites] Int J Hematol. 2003 Aug;78(2):133-8 [12953807.001]
  • [Cites] Blood. 1999 Apr 1;93(7):2191-5 [10090926.001]
  • [Cites] Br J Haematol. 2009 Jan;144(2):206-16 [19036108.001]
  • [Cites] Pediatr Blood Cancer. 2004 Oct;43(5):545-51 [15382271.001]
  • [Cites] Ann Intern Med. 1999 Feb 2;130(3):193-201 [10049197.001]
  • [Cites] Blood. 1997 May 15;89(10):3890-1 [9160700.001]
  • [Cites] Blood. 1987 Oct;70(4):1046-52 [3651599.001]
  • [Cites] Zhonghua Er Ke Za Zhi. 2008 Dec;46(12):909-13 [19134253.001]
  • (PMID = 20524094.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Androgens; 0 / Immunosuppressive Agents; 83HN0GTJ6D / Cyclosporine; L76T0ZCA8K / Oxymetholone
  •  go-up   go-down


83. Serrano E, Carnicer MJ, Lasa A, Orantes V, Pena J, Brunet S, Aventín A, Sierra J, Nomdedéu JF: Epigenetic-based treatments emphasize the biologic differences of core-binding factor acute myeloid leukemias. Leuk Res; 2008 Jun;32(6):944-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epigenetic-based treatments emphasize the biologic differences of core-binding factor acute myeloid leukemias.
  • Acute myeloid leukemia (AML) is a heterogeneous group of disorders characterized by an abnormal proliferation of the myeloid precursors and a maturation block.
  • The most common chromosomal lesions in AML are the t(8;21) and inv(16).
  • To better understand the leukemogenic mechanism of these fusion proteins, we performed gene expression studies in samples from (8;21), AML1 mutated and inv(16) patients, as well as from the Kasumi-1 cell line and a U937 cell line expressing the AML1-ETO fusion gene.
  • To assess the influence of associated epigenetic lesions, we performed gene expression studies in Kasumi-1 cells and cells extracted from an Inv(16) patient, both treated with demethylating and HDAC inhibitor agents.
  • Furthermore, some of the genes deregulated by the leukemogenic process reverted to their normal expression with demethylating and HDAC inhibitor treatment, highlighting the role of chromatin remodeling processes in AML.
  • [MeSH-major] Core Binding Factor Alpha 2 Subunit / metabolism. DNA Methylation. Enzyme Inhibitors / pharmacology. Epigenesis, Genetic / drug effects. Leukemia, Myeloid, Acute / drug therapy. Leukemia, Myeloid, Acute / genetics
  • [MeSH-minor] Adult. Azacitidine / analogs & derivatives. Azacitidine / pharmacology. Biomarkers, Tumor / genetics. Chromatin Assembly and Disassembly. Chromosome Inversion / genetics. Chromosomes, Human, Pair 16 / genetics. Chromosomes, Human, Pair 21 / genetics. Chromosomes, Human, Pair 8 / genetics. DNA Modification Methylases / antagonists & inhibitors. Gene Expression Profiling. Gene Expression Regulation, Leukemic / drug effects. Histone Deacetylase Inhibitors. Humans. Hydroxamic Acids / pharmacology. Mutation / genetics. Oligonucleotide Array Sequence Analysis. Oncogene Proteins, Fusion / genetics. Promoter Regions, Genetic. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Translocation, Genetic. Tumor Cells, Cultured. U937 Cells

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. AZACITIDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18206229.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / AML1-ETO fusion protein, human; 0 / Biomarkers, Tumor; 0 / CBFbeta-MYH11 fusion protein; 0 / Core Binding Factor Alpha 2 Subunit; 0 / Enzyme Inhibitors; 0 / Histone Deacetylase Inhibitors; 0 / Hydroxamic Acids; 0 / Oncogene Proteins, Fusion; 0 / RNA, Messenger; 3X2S926L3Z / trichostatin A; 776B62CQ27 / decitabine; EC 2.1.1.- / DNA Modification Methylases; M801H13NRU / Azacitidine
  •  go-up   go-down


84. Hahn-Ast C, Glasmacher A, Mückter S, Schmitz A, Kraemer A, Marklein G, Brossart P, von Lilienfeld-Toal M: Overall survival and fungal infection-related mortality in patients with invasive fungal infection and neutropenia after myelosuppressive chemotherapy in a tertiary care centre from 1995 to 2006. J Antimicrob Chemother; 2010 Apr;65(4):761-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Sixty-three percent of chemotherapy courses were given to treat acute myeloid leukaemia, with the rest for acute lymphoblastic leukaemia or aggressive lymphoma.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Drug-Related Side Effects and Adverse Reactions. Hematologic Neoplasms / drug therapy. Mycoses / mortality. Neutropenia / chemically induced. Survival Analysis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Humans. Immunocompromised Host. Male. Middle Aged. Retrospective Studies. Surveys and Questionnaires. Treatment Outcome. Young Adult


85. Chu CY, Chiu HC: Chemotherapy-induced recall dermatitis on a previously scalded wound in a patient with acute myeloid leukaemia. Acta Derm Venereol; 2003;83(5):382-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy-induced recall dermatitis on a previously scalded wound in a patient with acute myeloid leukaemia.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Drug Eruptions / etiology. Drug Eruptions / immunology
  • [MeSH-minor] Adult. Burns / immunology. Cicatrix / immunology. Female. Humans. Leukemia, Myelomonocytic, Acute / drug therapy. Recurrence

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14609113.001).
  • [ISSN] 0001-5555
  • [Journal-full-title] Acta dermato-venereologica
  • [ISO-abbreviation] Acta Derm. Venereol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


86. Kang SJ, Park KH, Jung SI, Jang HC, Ji SY, Ahn JS, Kim HJ, Shin JH, Kim DM: Scrub typhus induced by peripheral blood stem cell transplantation in the immunocompromised patient: diagnostic usefulness of nested polymerase chain reaction. Transfusion; 2010 Feb;50(2):467-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Scrub typhus induced by peripheral blood stem cell transplantation in the immunocompromised patient: diagnostic usefulness of nested polymerase chain reaction.
  • This is a case report of scrub typhus contraction in an acute leukemia patient by transfusion of peripheral blood stem cells collected during the incubation period.
  • This type of incident shows the need to heighten awareness of the threat of rickettsial agents in transfused blood.
  • Nested PCR is a useful diagnostic method to confirm the diagnosis during incubation period and in the early phase of disease, especially for immunocompromised patients.
  • [MeSH-major] Leukemia, Myeloid, Acute / complications. Orientia tsutsugamushi / isolation & purification. Peripheral Blood Stem Cell Transplantation / adverse effects. Polymerase Chain Reaction / methods. Scrub Typhus / transmission
  • [MeSH-minor] Adult. Antibodies, Bacterial / blood. Base Sequence. DNA, Bacterial / genetics. Diagnostic Errors. Female. Fever / etiology. Graft vs Host Disease / diagnosis. Humans. Immunocompromised Host. Immunosuppressive Agents / adverse effects. Infectious Disease Incubation Period. Living Donors. Male. Molecular Sequence Data. Sequence Alignment. Sequence Homology, Nucleic Acid. Transplantation, Homologous / adverse effects

  • Genetic Alliance. consumer health - Transplantation.
  • Genetic Alliance. consumer health - Typhus.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19843286.001).
  • [ISSN] 1537-2995
  • [Journal-full-title] Transfusion
  • [ISO-abbreviation] Transfusion
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Bacterial; 0 / DNA, Bacterial; 0 / Immunosuppressive Agents
  •  go-up   go-down


87. Derbel O, Cannas G, Le QH, Elhamri M, Chelghoum Y, Nicolas-Virelizier E, Nicolini F, Troncy J, Barraco F, Michallet M, Thomas X: A single dose pegfilgrastim for supporting neutrophil recovery in patients treated for high-risk acute myeloid leukemia by the EMA 2000 schedule. Hematology; 2010 Jun;15(3):125-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A single dose pegfilgrastim for supporting neutrophil recovery in patients treated for high-risk acute myeloid leukemia by the EMA 2000 schedule.
  • Dose intensity has been demonstrated to be one determinant for treatment efficacy in younger adults with high-risk (relapsed and refractory) acute myelogenous leukemia.
  • The major non-hematologic toxicities were severe infections but despite this 23 remitters could proceed to their post-remission treatment, although 13 did not because of severe toxicity or early relapse.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Granulocyte Colony-Stimulating Factor / administration & dosage. Leukemia, Myeloid, Acute / blood. Leukemia, Myeloid, Acute / drug therapy. Neutropenia / drug therapy
  • [MeSH-minor] Adult. Cytarabine / administration & dosage. Cytarabine / adverse effects. Drug Administration Schedule. Etoposide / administration & dosage. Etoposide / adverse effects. Female. Filgrastim. Humans. Male. Middle Aged. Mitoxantrone / administration & dosage. Mitoxantrone / adverse effects. Prognosis. Recombinant Proteins. Remission Induction. Survival Analysis. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. Filgrastim .
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20557669.001).
  • [ISSN] 1607-8454
  • [Journal-full-title] Hematology (Amsterdam, Netherlands)
  • [ISO-abbreviation] Hematology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Recombinant Proteins; 04079A1RDZ / Cytarabine; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 3A58010674 / pegfilgrastim; 6PLQ3CP4P3 / Etoposide; BZ114NVM5P / Mitoxantrone; PVI5M0M1GW / Filgrastim
  •  go-up   go-down


88. Baird R, van Zyl-Smit RN, Iveson A, Duddy J, Rassam SM: Thalidomide is highly effective in a patient with meningeal acute myeloid leukaemia. Leuk Lymphoma; 2004 Jan;45(1):179-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thalidomide is highly effective in a patient with meningeal acute myeloid leukaemia.
  • We report a case of secondary acute myeloid leukaemia (AML) following high dose therapy for diffuse large B-cell non-Hodgkin's lymphoma (NHL) who developed meningeal leukaemia.
  • Thalidomide has been reported to have anti-AML activity and appears to cross the blood brain barrier (BBB).
  • [MeSH-major] Leukemia, Erythroblastic, Acute / drug therapy. Meningeal Neoplasms / drug therapy. Thalidomide / therapeutic use
  • [MeSH-minor] Adult. Fatal Outcome. Female. Humans. Lymphoma, B-Cell / complications. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / radiotherapy

  • Hazardous Substances Data Bank. THALIDOMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15061217.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 4Z8R6ORS6L / Thalidomide
  •  go-up   go-down


89. Jurcic JG, DeBlasio T, Dumont L, Yao TJ, Scheinberg DA: Molecular remission induction with retinoic acid and anti-CD33 monoclonal antibody HuM195 in acute promyelocytic leukemia. Clin Cancer Res; 2000 Feb;6(2):372-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular remission induction with retinoic acid and anti-CD33 monoclonal antibody HuM195 in acute promyelocytic leukemia.
  • Despite achieving complete remission with retinoic acid (RA), most patients with acute promyelocytic leukemia (APL) have minimal residual disease detectable by reverse transcription-PCR (RT-PCR) amplification.
  • HuM195, a humanized monoclonal antibody reactive with the cell surface antigen CD33, specifically targets and kills myeloid leukemia cells.
  • Among similar patients treated on earlier studies, 7 of 34 patients (21%) induced into remission with RA and then maintained on the drug for 1 month were RT-PCR negative before chemotherapy (P = 0.07).
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Leukemia, Promyelocytic, Acute / drug therapy. Tretinoin / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Aged. Antigens, CD / immunology. Antigens, Differentiation, Myelomonocytic / immunology. Disease-Free Survival. Female. Humans. Male. Middle Aged. Remission Induction. Sialic Acid Binding Ig-like Lectin 3. Time Factors

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • Hazardous Substances Data Bank. ALITRETINOIN .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10690513.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / FDA HHS / FD / FD-R-000925-01; United States / FDA HHS / FD / FD-R-00764; United States / NCI NIH HHS / CA / R01 CA55349; etc
  • [Publication-type] Clinical Trial; Controlled Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / Antineoplastic Agents; 0 / CD33 protein, human; 0 / Sialic Acid Binding Ig-like Lectin 3; 0 / monoclonal antibody M195; 5300-03-8 / alitretinoin; 5688UTC01R / Tretinoin
  •  go-up   go-down


90. Büchner T, Berdel WE, Schoch C, Haferlach T, Serve HL, Kienast J, Schnittger S, Kern W, Tchinda J, Reichle A, Lengfelder E, Staib P, Ludwig WD, Aul C, Eimermacher H, Balleisen L, Sauerland MC, Heinecke A, Wörmann B, Hiddemann W: Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukemia. J Clin Oncol; 2006 Jun 1;24(16):2480-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukemia.
  • PURPOSE: Intensification by high-dose cytarabine in postremission or induction therapy and prolonged maintenance are established strategies to improve the outcome in patients with acute myeloid leukemia (AML).
  • PATIENTS AND METHODS: A total of 1,770 patients (age 16 to 85 years) with de novo or secondary AML or high-risk myelodysplastic syndrome (MDS) were randomly assigned upfront for induction therapy containing one course with standard dose and one course with high-dose cytarabine, or two courses with high-dose cytarabine, and in the same step received postremission prolonged maintenance or busulfan/cyclophosphamide chemotherapy with autologous stem-cell transplantation.
  • There was no significant difference in any prognostic subgroup according to secondary AML/MDS, cytogenetics, WBC, lactate dehydrogenase, and early blast clearance.
  • CONCLUSION: The regimen of one course with standard-dose cytarabine and one course with high-dose cytarabine for induction, and prolonged maintenance for postremission chemotherapy in patients with AML is not improved by additional escalation in cytotoxic treatment.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hematopoietic Stem Cell Transplantation. Leukemia, Myeloid / drug therapy. Leukemia, Myeloid / surgery. Myelodysplastic Syndromes / drug therapy. Myelodysplastic Syndromes / surgery
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Age Factors. Aged. Aged, 80 and over. Cytarabine / administration & dosage. Drug Administration Schedule. Female. Humans. L-Lactate Dehydrogenase / blood. Leukocyte Count. Male. Middle Aged. Mitoxantrone / administration & dosage. Multivariate Analysis. Prognosis. Prospective Studies. Remission Induction. Risk Factors. Transplantation, Autologous. Treatment Outcome

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Myelodysplastic Syndromes.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2006 Dec 1;24(34):5471-2; author reply 5472-3 [17135654.001]
  • [ErratumIn] J Clin Oncol. 2011 Jul 1;29(19):2739
  • (PMID = 16735702.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; BZ114NVM5P / Mitoxantrone; EC 1.1.1.27 / L-Lactate Dehydrogenase
  •  go-up   go-down


91. Sunnaram BL, Gandemer V, Sebillot M, Grandgirard N, Amiot L, Leray E, Goasguen JE: LRP overexpression in monocytic lineage. Leuk Res; 2003 Aug;27(8):755-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The failure to chemotherapy is a multi factorial phenomenon and lung resistance protein (LRP) overexpression has already been discussed as implicated in drug resistance.
  • The observation of a strong and unusual expression of LRP in acute myeloid leukemia (AML) with monocytic component led us to test (for P170 and LRP) a new series of 47 AML with different FAB subtypes.
  • The strongest LRP overexpression was also found in chronic myelomonocytic leukemia (four cases), reactive monocytosis (three cases) and in a dendritic cell line.
  • [MeSH-major] Leukemia, Myeloid / pathology. Monocytes / chemistry. Neoplasm Proteins / analysis
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal. Cell Lineage. Child. Child, Preschool. Female. Glycoproteins / analysis. Humans. Immunohistochemistry. Infant. Infant, Newborn. Male. Middle Aged. Survival Rate. Vault Ribonucleoprotein Particles

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12801535.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Glycoproteins; 0 / Neoplasm Proteins; 0 / Vault Ribonucleoprotein Particles; 0 / major vault protein; 0 / p-170 glycoprotein, human
  •  go-up   go-down


92. Kawai A, Sugihara S, Naito N, Ozaki T, Isu K, Hatae Y, Inoue H: Development of acute myeloid leukemia after chemotherapy for osteosarcoma. Clin Orthop Relat Res; 2001 Oct;(391):239-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Development of acute myeloid leukemia after chemotherapy for osteosarcoma.
  • The current study describes two patients with osteosarcoma who had acute myeloid leukemia develop after treatment with multiagent chemotherapy.
  • The deoxyribonucleic acid-damaging activity of doxorubicin reinforced by the use of alkylating agents is highly suspected as a causative event in the development of leukemia after treatment of osteosarcoma.
  • As the next step in the development of treatment for patients with osteosarcoma, the type and intensity of treatment must be evaluated to minimize possible leukemogenic effects without compromising the potential for cure.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Bone Neoplasms / drug therapy. Leukemia, Myeloid / chemically induced. Osteosarcoma / drug therapy
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Female. Humans. Male


93. Bruserud O, Gjertsen BT, von Volkman HL: In vitro culture of human acute myelogenous leukemia (AML) cells in serum-free media: studies of native AML blasts and AML cell lines. J Hematother Stem Cell Res; 2000 Dec;9(6):923-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vitro culture of human acute myelogenous leukemia (AML) cells in serum-free media: studies of native AML blasts and AML cell lines.
  • The functional characteristics were compared for acute myelogenous leukemia (AML) cells (native blasts and AML cell lines) cultured in three serum-free media (X-vivo 10, X-vivo 15, [Bio-Whitacker, Walkersville, MD] and StemSpan [Stem Cell Technologies, Vancouver, BC, Canada]) and in medium containing 10% inactivated fetal calf serum (FCS).
  • For native AML blasts the following functions were compared:.
  • AML blast proliferation differed between patients independent of the culture medium used, and clonogenic cells were maintained after in vitro culture in all media.
  • Native AML blasts incubated in StemSpan also showed a low frequency of apoptotic cells.
  • The three serum-free media could also be used for long-term expansion of well-characterized AML cell lines, but the optimal medium for cell expansion and cytokine secretion differed between cell lines.
  • We conclude that standardized serum-free culture conditions can be used for in vitro studies of native AML blasts and AML cell lines.
  • [MeSH-major] Leukemia, Myeloid, Acute / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Apoptosis / drug effects. Cell Culture Techniques. Cell Division / drug effects. Clone Cells / drug effects. Clone Cells / pathology. Culture Media / pharmacology. Culture Media, Serum-Free. Cytokines / pharmacology. Cytokines / secretion. Female. Humans. Lymphocyte Activation / drug effects. Male. Middle Aged. Stem Cells / drug effects. Tumor Cells, Cultured / drug effects

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11177606.001).
  • [ISSN] 1525-8165
  • [Journal-full-title] Journal of hematotherapy & stem cell research
  • [ISO-abbreviation] J. Hematother. Stem Cell Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Culture Media; 0 / Culture Media, Serum-Free; 0 / Cytokines
  •  go-up   go-down


94. Canada TW, Weavind LM, Augustin KM: Possible liposomal amphotericin B-induced nephrogenic diabetes insipidus. Ann Pharmacother; 2003 Jan;37(1):70-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CASE SUMMARY: A 38-year-old white man with relapsed acute myelogenous leukemia underwent a matched unrelated donor allogeneic bone marrow transplant with adequate engraftment and mild graft-versus-host disease responding to corticosteroids.
  • [MeSH-major] Amphotericin B / adverse effects. Antifungal Agents / adverse effects. Diabetes Insipidus, Nephrogenic / chemically induced
  • [MeSH-minor] Adult. Bone Marrow Transplantation / adverse effects. Candida glabrata. Dose-Response Relationship, Drug. Humans. Injections, Intravenous. Leukemia, Myeloid, Acute / therapy. Male. Pneumonia / drug therapy. Pneumonia / microbiology

  • Genetic Alliance. consumer health - Diabetes.
  • Genetic Alliance. consumer health - Diabetes Insipidus.
  • Genetic Alliance. consumer health - Nephrogenic diabetes insipidus.
  • Hazardous Substances Data Bank. AMPHOTERICIN B .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12503936.001).
  • [ISSN] 1060-0280
  • [Journal-full-title] The Annals of pharmacotherapy
  • [ISO-abbreviation] Ann Pharmacother
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antifungal Agents; 0 / liposomal amphotericin B; 7XU7A7DROE / Amphotericin B
  •  go-up   go-down


95. Suzuki S, Uozumi K, Hanada S, Lin XY, Ohno N, Takatsuka Y, Takeuchi S, Owatari S, Takeshita T, Arima T: A novel c-kit positive biphenotypic acute leukemia cell line, TMBL-1, carrying a p53 point mutation. Leuk Lymphoma; 2003 May;44(5):849-57
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A novel c-kit positive biphenotypic acute leukemia cell line, TMBL-1, carrying a p53 point mutation.
  • We established and characterized a c-kit positive cell line from the bone marrow of a patient with biphenotypic acute leukemia (BAL).
  • The immunophenotype of the primary leukemia cells at diagnosis was cytoplasmic CD3+, CD7+, CD13+, CD33-, interleukin-7 (IL-7) receptor+ and c-kit -.
  • However, leukemia cells in relapse and TMBL-1 cells were CD33+ and c-kit +.
  • Immunophenotypically, TMBL-1 is a BAL cell line that coexpresses T-lymphoid and myeloid markers which fulfill the criteria of the European Group for the Immunological Characterization of Leukemia.
  • Primary leukemia cells in relapse also carried the same point mutation but not at diagnosis.
  • The biphenotypic features and p53 mutation may be associated with progression to a more malignant type.
  • This cell line may provide new information on the role of SCF in the overlapping area between early T-lymphoid/myeloid cells, and help in the design of new therapies targeted towards p53 mutations.
  • [MeSH-major] Leukemia / pathology. Point Mutation. Proto-Oncogene Proteins c-kit. Tumor Cells, Cultured. Tumor Suppressor Protein p53 / genetics
  • [MeSH-minor] Adult. Bone Marrow Cells. Cell Division / drug effects. Humans. Immunophenotyping. Male. Myeloid Cells / pathology. Paclitaxel / pharmacology. Stem Cell Factor / pharmacology. T-Lymphocytes / pathology

  • Genetic Alliance. consumer health - Acute Biphenotypic Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • Hazardous Substances Data Bank. TAXOL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12802925.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Stem Cell Factor; 0 / Tumor Suppressor Protein p53; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


96. Slavin MA, Heath CH, Thursky KA, Morrissey CO, Szer J, Ling LM, Milliken ST, Grigg AP: Antifungal prophylaxis in adult stem cell transplantation and haematological malignancy. Intern Med J; 2008 Jun;38(6b):468-76
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antifungal prophylaxis in adult stem cell transplantation and haematological malignancy.
  • Antifungal prophylaxis can be recommended in patients undergoing induction chemotherapy for acute myeloid leukemia and treatment for grade 2 or greater or chronic extensive graft versus host disease.
  • The decision to use prophylaxis and which agent to use will be influenced by effectiveness, number needed to treat and the likelihood of toxicity and drug interactions.
  • The availability of rapid diagnostic tests for fungal infection and institutional epidemiology will also influence the need for and choice of prophylaxis.
  • Whilst prophylaxis can be beneficial, it may impede the ability to make a rapid diagnosis of fungal infection by reducing the yield of diagnostic tests and change the epidemiology of fungal infection.
  • As non-culture based diagnostic tests are refined and become more available there may be a shift from prophylaxis to early diagnosis and treatment.
  • [MeSH-major] Antifungal Agents / therapeutic use. Leukemia, Myeloid / therapy. Mycoses / prevention & control. Opportunistic Infections / prevention & control. Stem Cell Transplantation
  • [MeSH-minor] Adult. Humans. Neutropenia / complications

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Fungal Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18588520.001).
  • [ISSN] 1445-5994
  • [Journal-full-title] Internal medicine journal
  • [ISO-abbreviation] Intern Med J
  • [Language] eng
  • [Publication-type] Journal Article; Practice Guideline
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antifungal Agents
  •  go-up   go-down


97. Negaard HF, Iversen PO, Østenstad B, Iversen N, Holme PA, Sandset PM: Hypercoagulability in patients with haematological neoplasia: no apparent initiation by tissue factor. Thromb Haemost; 2008 Jun;99(6):1040-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Since anti-haemostatic agents are studied in clinical trials for their potential to prolong survival in cancer patients, a detailed characterisation of haemostatic markers in cancer subtypes is needed.
  • Hence, in this study, we measured the plasma concentrations and mRNA expression in blood mononuclear cells of haemostatic parameters in 93 patients with haematological neoplasias (acute myeloid leukaemia, chronic lymphatic leukaemia, multiple myeloma, and non-Hodgkin's lymphoma) before start and after completion of cancer therapy.
  • At diagnosis we found activation of coagulation and fibrinolysis, especially in patients with acute myeloid leukaemia.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers / blood. Case-Control Studies. Factor VII / metabolism. Female. Fibrin Fibrinogen Degradation Products / metabolism. Glycoproteins / blood. Humans. Leukemia, Lymphocytic, Chronic, B-Cell / blood. Leukemia, Lymphocytic, Chronic, B-Cell / complications. Leukemia, Myeloid, Acute / blood. Leukemia, Myeloid, Acute / complications. Lipoproteins / blood. Longitudinal Studies. Lymphoma, Non-Hodgkin / blood. Lymphoma, Non-Hodgkin / complications. Male. Middle Aged. Multiple Myeloma / blood. Multiple Myeloma / complications. Norway. Peptide Fragments / blood. Prothrombin. RNA, Messenger / blood. Thromboplastin / metabolism

  • MedlinePlus Health Information. consumer health - Deep Vein Thrombosis.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18521506.001).
  • [ISSN] 0340-6245
  • [Journal-full-title] Thrombosis and haemostasis
  • [ISO-abbreviation] Thromb. Haemost.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Fibrin Fibrinogen Degradation Products; 0 / Glycoproteins; 0 / Lipoproteins; 0 / Peptide Fragments; 0 / RNA, Messenger; 0 / fibrin fragment D; 0 / lipoprotein-associated coagulation inhibitor; 0 / prothrombin fragment 1.2; 0 / tissue-factor-pathway inhibitor 2; 9001-25-6 / Factor VII; 9001-26-7 / Prothrombin; 9035-58-9 / Thromboplastin
  •  go-up   go-down


98. Siehl JM, Reinwald M, Heufelder K, Menssen HD, Keilholz U, Thiel E: Expression of Wilms' tumor gene 1 at different stages of acute myeloid leukemia and analysis of its major splice variants. Ann Hematol; 2004 Dec;83(12):745-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of Wilms' tumor gene 1 at different stages of acute myeloid leukemia and analysis of its major splice variants.
  • WT1 is a transcription factor involved in differentiation and proliferation of acute myeloid leukemia (AML) blasts and is expressed in 90% of cases, as determined by nested reverse transcription polymerase chain reaction (RT-PCR).
  • It is proposed to be a key molecule in leukemia promotion.
  • To assess the relevance of WT1 expression, we analyzed blood and bone marrow samples from 58 AML patients (37 at diagnosis, 8 in hematological remission, and 13 at relapse) for the level of WT1 expression, using quantitative real-time RT-PCR.
  • Together, these findings support the potential of WT1 as a target for novel treatment approaches in AML.
  • [MeSH-major] Gene Expression Regulation, Leukemic. Leukemia, Myeloid, Acute / genetics. RNA Splicing / genetics. RNA, Neoplasm / genetics. WT1 Proteins / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Bone Marrow Cells / metabolism. Bone Marrow Cells / pathology. Cell Differentiation / genetics. Drug Delivery Systems. Female. Humans. Male. Middle Aged. Protein Isoforms / genetics. Protein Isoforms / metabolism. Recurrence. Reverse Transcriptase Polymerase Chain Reaction


99. Gabriel DA, Shea TC, Serody JS, Moore DT, Kirby SL, Harvey D, Krasnov C: Cytoprotection by amifostine during autologous stem cell transplantation for advanced refractory hematologic malignancies. Biol Blood Marrow Transplant; 2005 Dec;11(12):1022-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Thirty-five patients (20 with non-Hodgkin lymphoma, 12 with Hodgkin disease, and 3 with acute myelogenous leukemia) who underwent autologous stem cell transplantation were conditioned with total body irradiation 2 Gy twice daily on days -8 through -6; cyclophosphamide 6 g/m(2), etoposide 1.8 g/m(2), and carboplatin 1 g/m(2) on days -5 through -3; and amifostine 500 mg/m(2) on days -8 through -2.
  • [MeSH-major] Amifostine / administration & dosage. Hematopoietic Stem Cell Transplantation. Hodgkin Disease / therapy. Leukemia, Myeloid / therapy. Lymphoma, Non-Hodgkin / therapy. Radiation-Protective Agents / administration & dosage. Transplantation Conditioning
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Cytoprotection / drug effects. Female. Graft Survival / drug effects. Humans. Male. Middle Aged. Myeloablative Agonists / administration & dosage. Narcotics / administration & dosage. Parenteral Nutrition / methods. Prospective Studies. Time Factors. Transplantation, Autologous. Whole-Body Irradiation / methods

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. AMIFOSTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16338625.001).
  • [ISSN] 1083-8791
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Myeloablative Agonists; 0 / Narcotics; 0 / Radiation-Protective Agents; M487QF2F4V / Amifostine
  •  go-up   go-down


100. Kim LC, Rix U, Haura EB: Dasatinib in solid tumors. Expert Opin Investig Drugs; 2010 Mar;19(3):415-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It has gained much attention for its use in chronic myeloid leukemia and for the treatment of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia.
  • TAKE HOME MESSAGE: In reviewing the clinical safety data of dasatinib in its current use as a Src inhibitor in a wide variety of solid malignancies, dasatinib appears to be safe and is a promising agent for the treatment of metastatic solid tumors refractory to standard therapies.
  • [MeSH-major] Neoplasms / drug therapy. Protein Kinase Inhibitors / therapeutic use. Pyrimidines / therapeutic use. Thiazoles / therapeutic use
  • [MeSH-minor] Adult. Clinical Trials, Phase I as Topic. Clinical Trials, Phase II as Topic. Dasatinib. Humans. Neoplasm Metastasis. src-Family Kinases / antagonists & inhibitors. src-Family Kinases / metabolism

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20113198.001).
  • [ISSN] 1744-7658
  • [Journal-full-title] Expert opinion on investigational drugs
  • [ISO-abbreviation] Expert Opin Investig Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Protein Kinase Inhibitors; 0 / Pyrimidines; 0 / Thiazoles; EC 2.7.10.2 / src-Family Kinases; RBZ1571X5H / Dasatinib
  • [Number-of-references] 58
  •  go-up   go-down






Advertisement